Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Antimicrobial Peptides: a New Frontier in Antifungal Therapy

Giuseppe Buda De Cesare, Shane A. Cristy, Danielle A. Garsin and 1 more

mBio · 2020 · Review · CC BY

doi:10.1128/mbio.02123-20

Abstract

Invasive fungal infections in humans are generally associated with high mortality, making the choice of antifungal drug crucial for the outcome of the patient. The limited spectrum of antifungals available and the development of drug resistance represent the main concerns for the current antifungal treatments, requiring alternative strategies. Antimicrobial peptides (AMPs), expressed in several organisms and used as first-line defenses against microbial infections, have emerged as potential candidates for developing new antifungal therapies, characterized by negligible host toxicity and low resistance rates.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

The threat of fungal infections is increasing, caused in part by the recent advances in health care therapies that have expanded the population of immunosuppressed patients. Unfortunately, the repertoire of effective antifungal agents remains very limited, with only three classes of drugs available for systemic therapy: the polyenes (e.g., amphotericin B), triazoles (e.g., fluconazole), and echinocandins (e.g., caspofungin). A few other drugs (e.g., 5-flucytosine) are available for adjunctive treatments. Furthermore, the limited spectrum and widespread use of antifungal agents have augmented the emergence of drug-resistant strains of Candida, Cryptococcus, and Aspergillus. In addition, a number of fungal pathogens, including the Mucorales, Candida auris, and some molds, are intrinsically resistant to these agents and difficult to treat at present, emphasizing the need for alternative antifungal strategies.

Antimicrobial peptides (AMPs) were first described in 1939 by Dubos, who isolated gramicidin from Bacillus brevis and assessed its antibacterial properties against infections in mice. A few years later, in 1948, another peptide family was isolated from Bacillus subtilis, bacillomycin, with low antibacterial effects but remarkable antifungal activity. The immunomodulatory functions of AMPs were later described and, together with activity against a broad range of microorganisms, aroused interest in their potential therapeutic applications.

While the focus of most of the current studies is on antibacterial peptides, there are many with antifungal properties, and this review will highlight antifungal peptides as important potential additions to the antifungal repertoire. Here, we use the term peptide in a broad sense, including proteins of any length as well as some compounds in which peptides are conjugated to non-amino acid moieties. Furthermore, we focus on the activities and mechanisms of these AMPs; the challenges and benefits of clinical development of these compounds were recently discussed elsewhere.

BIOSYNTHESIS AND STRUCTURE OF AMPs

Antimicrobial peptides are synthesized by three routes (Fig. 1a). Ribosomally coded AMPs, such as human β-defensins and histatins, are typically short (<50 amino acids), cationic (net charge of +2 to +9) amphiphilic peptides found in bacteria, insects, vertebrates, and plants that are produced to fight microbial infections. The positive net charge, mainly due to lysine and arginine residues, promotes disruption of phospholipid-rich membranes. Other AMPs are generated by nonribosomal peptide synthases (NRPSs) (Fig. 1b), which are mainly found in bacteria (Actinomycetes and Bacilli, in particular) and filamentous fungi. The NRPS-generated AMPs are diverse due to the incorporation of nonproteinogenic amino acids into the sequence (often the d-enantiomers of natural residues) and are often heavily modified through hydroxylation, glycosylation, lipidation, and cyclization. Finally, some AMPs are generated through proteolytic cleavage of larger proteins with entirely separate functions and hence are called cryptic peptides (Fig. 1c).

The amphiphilic nature of many of the AMPs determines their structural flexibility. Contact with membranes can induce the formation of secondary structures, such as α-helices, β-sheets, or a mixture of both, that are critical to antimicrobial activity. Cyclic peptides can be stabilized through intramolecular disulfide bonds and form helical type II structures, specifically promoted by arginine, histidine, and proline residues, while other peptides maintain a linear configuration. Some AMPs, such as gramicidin A and tritrpticin, are rich in tryptophan, a residue common in transmembrane segments especially close the membrane-water interface. As a result, they induce the formation of ion channels in the target membranes. Other peptides, such as the defensins, have a core containing two antiparallel β-sheets with an interposed short turn. Another important characteristic of many AMPs is their hydrophobicity, which is responsible for their membranolytic properties and correlates with low toxicity and selectivity toward mammalian cells.

RESISTANCE TO AMPs

AMPs represent one of the possible options to overcome the issue of antimicrobial resistance, partly because they are less susceptible than conventional antibiotics to the evolution of resistance from microorganisms. Although some episodes of resistance against AMPs were described, the “mutant selection window” (MSW), the concentration range in which selective amplification of single-step, drug-resistant mutants can occur, appears to be narrower than for conventional antibiotics. This results in a higher killing rate and lower probability of developing resistance. In many cases, the mechanism of action is based on fundamental cellular properties (e.g., negatively charged membranes) that are inherently difficult to change.

CLASSIFICATION OF ANTIFUNGAL PEPTIDES

The following paragraphs describe known antifungal peptides based on the mechanism of action: (i) peptides interacting with membranes, which usually form pores and can have broad-spectrum activity against bacteria as well as well as fungi, (ii) peptides targeting the cell wall, which are usually more specific toward fungi, (iii) nucleic acid inhibitors, and (iv) other peptides, which have either unique or unknown mechanisms of action. Relevant features of many of the peptides described below are summarized in Table S1 in the supplemental material and illustrated graphically in Fig. 2.

PORE-FORMING PEPTIDES

This class of peptides is the most common among all the AMPs found in nature, characterized by a broad range of activity toward different microorganisms and relatively high toxicity compared to that of other antimicrobials with bacterium- or fungus-specific targets. Their mechanisms of action can be described using different models of their effects on the target membranes with which they interact.

Barrel-stave model.

In the “barrel-stave model,” peptides aggregate and form barrel-shaped pores in the membranes, with the peptide helices acting as staves. Amphotericin B (AmB) is a polyene macrolide antibiotic produced by Streptomyces nodosus via a polyketide synthase and is, to date, the only natural product with antifungal effects exerted through this mechanism. It was long believed that binding of ergosterol in the fungal membrane resulted in pore formation, a rapid leakage of potassium and magnesium, and, ultimately, cell death. More recently, a secondary mechanism in which amphotericin physically extracts ergosterol from lipid bilayers was shown to contribute to the fungicidal activity. It remains to be seen which of these two mechanisms is more responsible for cidal activity, and it might differ from species to species. Accumulation of reactive oxygen species (ROS) also contributes to the antifungal effect of the drug.

Carpet model.

In the “carpet model,” peptides accumulate on the membrane in a carpet-like manner, attracted by electrostatic interactions. At high concentrations of the peptide, the membranes are disrupted and form micelles, with similar effects to treatment with detergents. The amphipathic dermaseptin peptides, produced by phyllomedusine frog skin, use this mechanism and are active against fungi, bacteria, protozoa, and viruses. In Candida albicans, dermaseptin-S1 inhibits growth and filamentation, confirmed by downregulation of several hypha-associated genes.

Also belonging to this group are the lipopeptides of the syringomycin family, secreted by the plant-associated bacterium Pseudomonas syringae, which are particularly active against several filamentous fungi and yeasts, including Candida, Cryptococcus, and Aspergillus strains. In addition to the formation of pores, they also induce passive ion fluxes, which generate an electrochemical gradient that alters the pH gradient across the membrane.

Cecropins, found in insects, are active against many fungi, including Aspergillus and Fusarium species (especially F. moniliforme [verticillioides] and F. oxysporum). In particular, cecropin A induces apoptosis associated with disrupted ion balances and intracellular glutathione redox states in C. albicans.

Toroidal pore model.

In the “toroidal pore model” the peptides insert into the membranes, forming pores and tilting the lipid layers in the fashion of a toroidal hole. One of the most studied AMPs in humans, LL-37 (CRAMP in mice), is part of this group. This cathelicidin-related peptide is produced by neutrophils and other cells of the innate immune system on epithelial surfaces, where they represent one of the first lines of defense against fungi. LL-37 interacts with the cell wall carbohydrates (the main mediators of Candida adhesion) and permeabilizes the plasma membrane, with subsequent ROS accumulation. Induced expression of CRAMP resulted in a reduction of C. albicans gastrointestinal (GI) colonization and a 50% decrease in mortality in antibiotic-treated mice, demonstrating its key role in innate immunity.

Protegrins are cathelicidin-related cationic peptides that form toroidal pores on the plasma membranes of several microorganisms, causing K+ imbalance and cell death. One of these compounds, the porcine protegrin-1 (PG-1), was particularly active against a broad range of fungi, including several Candida species (including drug-resistant strains) and Cryptococcus neoformans, whereas Aspergillus species were more resistant. In the same study, other cathelicidin peptides were tested, including an ovine (SMAP-29) and two bovine α-helical (BMAP-27 and BMAP-28) peptides, which were as effective as PG-1 but at generally higher MICs, particularly for Candida tropicalis, Candida glabrata, and Candida parapsilosis.

Melittin is a cationic amphipathic peptide found in the venom of the honey bee Apis mellifera. Its effect on Candida involves (toroidal) pore formation, caspase- and mitochondrion-dependent apoptotic mechanisms with ROS generation, disruption of mitochondrial membrane potential, and Ca2+ release from the endoplasmic reticulum. The effect on other fungi is less clear, with other components in the venom potentially responsible for the antimycotic properties.

Peptaibols are linear lipopeptides mainly produced as fungal secondary metabolites by NRPSs found in the Trichoderma, Hypocrea, Emericellopsis, and Boletus genera, some containing nonproteinogenic amino acids. They include many compounds with antifungal activity (reviewed in reference ). Their mechanism of action is mainly through alteration of membrane permeability by pore formation, which is the reason why they have such a wide range of targets (viruses, protozoa, helminths, and insects) and different degrees of toxicity to mammalian cells dependent on the particular compound. Some examples include heptaibin, which has inhibitory activity on the growth of C. albicans, C. neoformans, and Aspergillus fumigatus, hyporientalin A, with promising candidacidal activity and relatively low toxicity, atroviridins (A, B, C), effective against Aspergillus niger and F. oxysporum, longibrachins, displaying anti-Aspergillus effects, and septocylindrins (A and B), inhibiting C. albicans.

OTHER MEMBRANE-ACTIVE PEPTIDES

A number of antifungal AMPs exert their activity through interactions with membranes, though it is not clear whether they form pores (or what kind of pores) or disrupt membrane integrity through other mechanisms.

Plant defensins are highly stable cysteine-rich peptides with widespread activity against bacteria and fungi that have been extensively studied (see, for instance, reference for a review). Several have antifungal activity, hypothesized to act through either a carpet or toroidal pore model. Two members of this family, RsAFP2 and heliomycin, were shown to interact with the glucosylceramides on the plasma membrane of C. albicans and Pichia pastoris, inducing cell death by membrane permeabilization. Similarly, NaD1 displays candidacidal activity, activating the high-osmolarity glycerol (HOG) pathway due to ROS production and oxidative damage. PvD1, isolated from Phaseolus vulgaris seeds, has antifungal activity against Fusarium species (F. oxysporum, F. solani, and F. lateritium) and Candida species (C. albicans, C. tropicalis, C. parapsilosis, and C. guilliermondii). Other plant defensins with antifungal effects exerted through membrane permeabilization include Dm-AMP1 and the hevein-like Pn-AMP1 and Pn-AMP2.

Pr-1, from pumpkin, inhibits the growth of many fungi, including F. oxysporum, F. solani, and C. albicans, through membrane permeabilization yet did not show hemolytic activity on human red blood cells.

Thionins, with a structure similar to that of plant defensins, exert antifungal activity via an unclear mechanism. For example, the Capsicum annuum thionin (CaThi) caused membrane permeabilization in C. albicans, C. parapsilosis, and C. tropicalis, where it also induced oxidative stress. Yet, the intracellular localization of this peptide in C. albicans and C. tropicalis suggested a possible nuclear target. Similar findings were observed with F. solani, where the peptide also showed a synergistic effect with fluconazole.

The mechanisms of interaction of the human defensins with membranes are not as well characterized as those of their plant relatives. Some members of this family, which are produced by neutrophils and epithelial cells, have antifungal activity, including β-defensins HBD-1 and HBD-3 and α-defensins HNP-1 and HNP-2. These compounds, detected in salivary glands and secretions, cause membrane permeabilization in fungal pathogens but with different mechanisms: HBD-1 and HBD-2 deploy an ATP-independent mechanism, involving membrane permeabilization, whereas HNP-1 and HNP-2 stimulate cytotoxicity by an efflux of cellular ATP, similarly to histatin 5. Another member of the defensin family, rhesus θ-defensin 1 (RTD-1), displayed fungicidal activity against Candida species, including multidrug-resistant C. auris, through cell permeabilization associated with ATP release and intracellular ROS accumulation, similarly to histatins, though it was more rapid and did not require mitochondrial ATP production.

Iturin A is a lipopeptide produced by NRPSs in Bacillus species and is effective against Candida, Trichosporon, Fusarium, and Aspergillus spp. via a pore-dependent mechanism, causing cell wall damage, ROS accumulation, and Hog1-mitogen-activated protein kinase (MAPK) activation. Despite potent hemotoxic effects, mice infected with C. albicans and treated with iturin A and AmB survived better than those treated with either agent alone.

Skin-PYY is an antibacterial and antifungal peptide found on the skin extract of the arboreal frog Phyllomedusa bicolor, displaying similar pharmacological and structural properties as neuropeptide Y (NPY) and polypeptide Y (PPY) found in the brains and intestines, respectively, of multiple vertebrates. This amphibian peptide showed moderate effects on Aspergillus species (A. fumigatus and A. niger) but higher efficacy against C. albicans, Microsporum canis, Trichophyton rubrum, and Arthroderma simii and appeared to be cidal rather than static. Promisingly, a low toxicity was observed for mammalian erythrocytes and macrophages at concentrations severalfold above the MIC for C. albicans.

Aureobasidin A (AbA) is a cyclic nonribosomal depsipeptide produced by the black mold Aureobasidium pullulans that exhibits a strong fungicidal activity against Candida species, C. neoformans, Blastomyces dermatitidis, and Histoplasma capsulatum but not Aspergillus spp.. The antifungal effect is exerted through the noncompetitive inhibition of the inositol phosphorylceramide (IPC) synthase, responsible for the sphingolipid biosynthesis in fungi and essential for cell viability. Toxicity is low due to the absence of the target enzyme in mammalian cells. Some fungi, such as A. fumigatus and Aspergillus flavus, are resistant as a result of increased efflux, confirmed by the reduced sensitivity of AbA on the Saccharomyces cerevisiae strain overexpressing Pdr16, a phosphatidylinositol transfer protein.

Zeamatin is a 22-kDa peptide isolated from Zea mays seeds, but compounds of the same family have been isolated from Avena sativa, Sorghum bicolor, and Triticum aestivum. Its membrane-permeabilizing activity was effective on C. albicans, but Mucorales species were resistant. Synergistic activity with nikkomycin Z and clotrimazole was detected in a Candida vaginitis mouse model. It binds β-1,3-glucan, which could be an important step in exerting its membrane-related function and could explain the resistance of Mucorales spp., which lack this carbohydrate.

HP 2-20 is a cryptic peptide with antifungal and antibacterial properties derived from the N terminus of the ribosomal protein L1 (Rpl1) of Helicobacter pylori and disrupts membranes via pore formation. Promisingly, the peptide’s hemolytic activity against mammalian cells was low. These effects were tested only on C. albicans and Trichosporon beigelii, with a strong reduction of mortality observed in mice injected with a lethal dose of C. albicans.

Cm-p1 is a small hydrophilic peptide identified from the crude extract of the marine snail Cenchritis muricatus. The protein from which this is produced is not known, since another sequence (Cm-p2), sharing 70% similarity with Cm-p1, was also found as part of a larger protein in the same organism. The low hydrophobicity likely correlates with the lack of toxicity toward human red blood cells and RAW 264.7 cells as well as with the absence of antibacterial activity, although it exhibited broad-spectrum antifungal activity against C. albicans, T. rubrum, A. niger, and F. oxysporum. Cm-p5 is a synthetic peptide derived from Cm-p1, with an increased fungistatic effect on C. albicans and C. parapsilosis but with little toxicity to mammalian cell lines. The improved activity was due to the affinity toward phospholipids of fungal membranes (phosphatidylserine and phosphatidylethanolamine) but low interaction with ergosterol and mammalian membranes.

Glucan synthesis inhibitors.

β-Glucan, the major polysaccharide of the fungal cell wall, is a polymer of glucose moieties linked by β-(1,3)- or β-(1,6)-glycosidic bonds that form a branched network conferring strength to the cell wall. β-Glucan is of extreme importance for recognition of fungal pathogens by the host innate immune system via dectin-1, a specific receptor for β-(1,3)-glucan, which is essential for fungal recognition and induction of the immune response. The echinocandin drugs, in clinical use for almost 20 years, are synthetically optimized derivatives of several nonribosomal AMPs, including pneumocandins and echinocandin B, produced by some fungal species as secondary metabolites. They are noncompetitive inhibitors of β-(1,3)-glucan synthase, critical to generating the cell wall in most fungal pathogens. The noncompetitive inhibition of the catalytic subunit of this enzyme, encoded by the GSC and FKS genes, can be overcome by point mutations, found commonly among echinocandin-resistant isolates.

Pneumocandins are produced by Zalerion arboricola; pneumocandin A0 had potent fungicidal activity against C. albicans but also high hemolytic activity and lacks efficacy against A. flavus, A. fumigatus, C. neoformans, and other Candida species. Echinocandin B is a fungal lipopeptide isolated from Aspergillus nidulans with potent anti-Candida activity. To reduce the high toxicity of these compounds on mammalian cells, mainly caused by the hemolytic activity, semisynthetic analogues with much reduced toxicity to mammalian cells but similar antifungal activity, such as cilofungin, have been generated.

Three synthetic derivatives emerged from clinical development in the 1990s: caspofungin, anidulafungin, and micafungin. These drugs addressed most of the drawbacks of their natural progenitors, providing broader activity and lower toxicity. The extended-spectrum echinocandins showed fungicidal activity against Candida species, including those that are resistant to amphotericin B or fluconazole, and had fungistatic activity against Aspergillus species. Currently approved echinocandins have limitations related to emerging drug resistance and the need for intravenous delivery. Potential next-generation echinocandins such as SCY-078 (ibrexafungerp; Scynexis, Inc.), an intravenous and orally bioavailable glucan synthase inhibitor, may solve these problems. Additionally, it retains in vitro activity against echinocandin-resistant isolates of Candida species.

Other compounds of the same family of echinocandins, which could drive the development of new synthetic antifungals, include papulacandins, mulundocandins, fusacandins, corynecandins, pestiocandins, and WF11899. Although effective as antifungals, these lipopeptides were never clinically approved because of lower activity and/or higher toxicity then extended-spectrum echinocandins. Aculeacins also belong to this group of antifungal peptides but have lower toxicity as well as lower efficacy against filamentous fungi.

Chitin inhibitors.

Chitin is another essential component of the fungal cell wall. It is composed of N-acetylglucosamine moieties connected by β-(1,4) linkages, and it is important for cell viability and modulation of the host immune response. The amount of chitin in the wall varies according to the cell morphology: for example, C. albicans hyphae can have up to 10 times more N-acetylglucosamine than yeast cells. Increased content of chitin in the wall has also been linked with resistance to echinocandin drugs.

Nikkomycin Z, a dipeptide with a nucleoside sidechain synthesized by Streptomyces tendae, is a competitive inhibitor of chitin synthases. The inhibitory activity of nikkomycin Z was demonstrated on a variety of different organisms, including fungal plant pathogens. It is active against B. dermatitidis and Coccidioides immitis in vitro and in animal models, although a lower efficacy was seen for Histoplasma capsulatum. It has modest efficacy against A. fumigatus alone but synergizes with echinocandins, generating more successful outcomes. Similar results were obtained for the melanized fungus Alternaria infectoria, involved in opportunistic human infections and respiratory allergies. Nikkomycin Z also synergizes with caspofungin or micafungin against Candida biofilms, in particular, C. albicans and C. parapsilosis. In fact, the response to caspofungin involves a compensatory increase in chitin synthesis, and so the ability of nikkomycin Z to target chitin synthesis is a plausible mechanism to explain the synergy between these two drugs. Other combinatorial effects were observed with the azoles, in particular, fluconazole and itraconazole against C. albicans and C. parapsilosis and itraconazole versus C. immitis and A. fumigatus. The efficacy of this AMP in combinatorial therapy with existing antifungal drugs may improve outcomes and reduce the development of resistance. This peptide is under development as an orphan product for treatment of coccidioidomycosis, with phase I studies successfully completed and demonstrating excellent safety in healthy humans.

Similar to Nikkomycin Z, the polyoxins (A to L) are nucleoside-tripeptide antibiotics produced by the actinomycete Streptomyces cacaoi that inhibit chitin synthases. They are effective not only against phytopathogenic fungi, such as Botrytis cinerea and Alternaria kikuchiana, but also against human pathogens such as C. albicans and C. neoformans. In particular, polyoxin D causes altered cell morphology in C. albicans, with hyphal inhibition, swollen cells, sensitivity to osmotic changes, and a weakened cell wall, especially at the septum, resulting in an inability to bud. Similar effects were observed for C. neoformans, with a greater fungistatic activity detected when incubated with 2 mM polyoxin D, which completely depleted growth.

Rabbit defensins NP-3b, NP-4, and NP-1 were shown to be highly active against C. albicans, with NP-5 able to potentiate their effects, whereas only NP-1 was found effective against other medically important fungi, such as C. neoformans, with a much lower MIC for acapsular strains. NP-1 also has activity against Rhizopus oryzae as well as hyphae and germinating conidia of C. immitis and A. fumigatus, though not resting conidia. NP-2 also killed A. fumigatus hyphae. The action of this peptide family was hypothesized to be related to chitin sequestration, since their preincubation with purified chitin reduced activity against A. fumigatus.

Arthrichitin and FR-90403 are produced by Arthrinium phaeospermum and Kernia spp., respectively, and, similarly to nikkomycin Z, bind and inhibit chitin synthases Chs1 and Chs2 in C. albicans.

Mannan-binding peptides.

Mannan represents the outermost layer of the fungal cell wall and it is composed of mannan fibrils formed from heavily glycosylated proteins, with α- and β-linked oligomannosyl residues. These mannoproteins are involved in many processes, including biofilm formation, virulence, and adhesion.

One family of secondary metabolites that includes pradimicins and benanomicins targets cell wall mannan. Pradimicins (A to E) are polyketides produced by the actinomycete Actinomadura hibisca, whereas benanomicins were isolated from Actinoallomurus spadix. They demonstrated a moderate in vitro antifungal activity against a broad spectrum of organisms, including Candida and Aspergillus species and C. neoformans, but a remarkable in vivo efficacy in healthy and immunocompromised mice infected with C. albicans, C. neoformans, and A. fumigatus. Moreover, benanomicin A was also successful for in vivo treatment of Pneumocystis carinii pneumonia. Pradimicin A also showed fungicidal effects against pulmonary candidiasis and aspergillosis, vaginal candidiasis, and skin Trichophyton mentagrophytes infection in mice with intravenous or topical treatment. The antifungal activity of this family of nonribosomal peptides recognizes d-mannose in a manner similar to that for lectins in the presence on calcium, ultimately leading to cell death. In S. cerevisiae pradimicin A induced an apoptosis-like cell death through ROS accumulation. To date, no ribosomally produced AMPs are known to target mannans.

NUCLEIC ACID INHIBITORS

The AMPs in this section specifically target nucleic acid biosynthesis and metabolism. Although some of them have been proven to bind DNA, the antimicrobial mechanisms are not completely clear. For example, the activity of buforin II is associated with its specific interaction with the major groove of DNA, but how this is antifungal remains unclear. For their capacity to bind nucleic acids, these peptides are also used as antineoplastics (e.g., actinomycin D) and can therefore have significant host effects (e.g., indolicidin). In some cases, the toxicity issue can be overcome by using different formulations, such as liposomes or nanoparticles, which reduces the adverse effects for the host but preserves the activity of the compound.

Various species of Streptomyces synthesize actinomycins, a family of chromopeptide lactones with antifungal activity. In particular, activity against C. albicans was described for actinomycin D, RSP 01, and RSP 02. Actinomycin D is clinically useful as an antineoplastic and exerts its antifungal function by intercalating the DNA. The other two have been tested with promising results but are not used clinically. Both have structural similarity to actinomycin D and therefore could function in a similar manner.

Indolicidin is a tridecapeptide amide of the cathelicidin family, isolated from cytoplasmic granules of bovine neutrophils, with strong antifungal activity against T. beigelii, C. albicans, Candida krusei, and A. flavus but has only modest effects on P. carinii and C. glabrata. Its structure, characterized by 39% tryptophan and 23% proline, was initially thought to target only the cell membrane, but later studies showed that it binds DNA and possibly affects DNA processing enzymes and repair mechanisms. Although its nonselective activity causes toxicity in humans, liposomal formulations of indolicidin reduced toxicity in mice 100-fold and allowed sufficiently high dosing to successfully treat mice infected systemically with A. fumigatus. Other formulations, such as indolicidin-conjugated gold nanoparticles, were effective against fluconazole-resistant C. albicans. A graphene-indolicidin nanocomposite formulation treated disseminated candidiasis as effectively as fluconazole in mice.

Buforins are cryptic peptides isolated from the stomachs of toads and originate from pepsin-directed proteolysis of histone H2A. Buforin II is derived from buforin I and has greater antimicrobial potential, with activity against C. albicans and C. neoformans. Initially believed to cause membrane permeabilization, further studies demonstrated that buforin II penetrates membranes without forming pores, and a possible interaction with nucleic acids was suggested.

OTHER ANTIFUNGAL PEPTIDES

This final section lists the peptides with alternative and incompletely characterized antifungal mechanisms from the sections listed before. Some of them include disruption of the cell integrity (e.g., histatins and cystatins), modulatory properties (e.g., EntV and alpha melanocyte-stimulating hormone [α-MSH]), surface interactions (e.g., surfactins, VLL-28, and psoriasin).

The mechanisms of histatins, and in particular, histatin 5 (Hst5), have been the subject of debate but seem to have an intracellular target. Hst5 is a human salivary cationic peptide with fungicidal activity against Candida species other than C. glabrata (including C. albicans, C. krusei, C. tropicalis, C. parapsilosis, and C. guilliermondii). In C. albicans, Hst5 binds to Ssa1/2 proteins (the Hsp70 orthologs) present in the cell wall and, once internalized by translocation, induces the formation of reactive oxygen species (ROS) within the cell and the efflux of ATP and ions in a manner dependent on the plasma membrane Trk1 potassium transporter. Hst5-induced osmotic stress also contributes to cytotoxicity. Zinc binding potentiates the cytotoxic effects of Hst5 P113, a 12-amino-acid proteolytic product of Hst5 that retains substantial anti-Candida activity.

Cystatins are a family of peptides with antifungal properties on Candida and Aspergillus species. These compounds are naturally found in vertebrates, invertebrates, and plants and exert a competitive inhibition on cysteine proteases. The inhibitory effect on fungal species is not characterized but seems to be independent from the protease inhibitory activity observed against bacteria. The cystatin purified from chicken egg white displayed fungicidal effects on C. albicans, C. parapsilosis, and C. tropicalis, with only milder influence on C. glabrata, in a similar fashion to that of histatin 5. A recombinant amaranth cystatin showed inhibition of spore germination and growth of A. niger and Aspergillus parasiticus. The altered cell morphology and organelle integrity suggest a possible correlation of the fungicidal activity with disruption of cell integrity.

The cyanobacterial genera Lyngbya, Nostoc, and Hassallia produce hassallidins and lyngbyabellins (e.g., hectochlorin), which are two distinct families of cyclic peptides that showed potent activity against C. albicans and C. krusei. Both of these peptide families have significant toxicity in mammalian cells: hectochlorin hyperpolymerizes actin, while hassallidin A disrupts membranes, and so their potential as therapeutics is limited.

Cepacidines (A1 and A2), are glycopeptides produced by Burkholderia cepacia displaying antifungal properties superior to those of AmB. These glycopeptides were found to be active against several Candida species and other fungal pathogens, including C. neoformans, A. niger, M. canis, F. oxysporum, and T. rubrum, but the presence of human serum (50%) strongly reduced the antifungal effect, precluding their utilization as antifungals.

EntV is a 68-amino-acid AMP produced by Enterococcus faecalis that showed inhibitory effects on biofilm formation for C. albicans, C. tropicalis, C. parapsilosis, and C. glabrata. It also causes a strong reduction (≥50%) of preformed C. albicans biofilms. It conferred protection against C. albicans in nematode infection and oropharyngeal candidiasis murine models. It is ribosomally produced and undergoes several processing events after secretion. However, its mechanism of action is still unclear. It does not affect fungal viability at all, only hyphal morphogenesis, and therefore is considered to have an antivirulence effect.

Leucinostatin A, produced by Penicillium (Purpureocillium) lilacinum, is a peptide antibiotic that, despite displaying antifungal activity against Candida spp. (including C. albicans, C. krusei, C. tropicalis, and C. guilliermondii), is unsuitable for clinical use due to substantial host toxicity. More recently, it has received renewed interest due to its antitrypanosomal and antitumoral activities. Two other fungal products, helioferins A and B, synthesized by the parasitic fungus Mycogone rosea, as well as trichopolyns A and B, secreted by Trichoderma polysporum, showed inhibitory activity against Candida, but their mode of action is unknown and they exhibit significant cytotoxicity in mammalian cells.

Fengycins and surfactins are families of nonribosomal cyclic lipopeptides produced by Bacillus amyloliquefaciens, some of which have antifungal action, especially against C. albicans, C. tropicalis, and some Rhizopus and Fusarium species. Reduced growth, spore germination, and germ tube formation were some of the observed effects, and efficacy was enhanced when combined with ketoconazole. Furthermore, it was shown that some fengycin compounds were able to remove 25% to 100% of C. albicans biofilms grown on polystyrene plates. The mechanisms of action of the various surfactins and fengycins are diverse and not completely understood. Studies with different peptides have suggested they disrupt the membrane or cell wall, inhibit DNA synthesis, or lead to mitochondrial disruption. The hypothesis that surfactins are membrane-active substances was also supported by the inhibition of membrane fusion during invasion of epithelial cells by enveloped viruses.

The alpha melanocyte-stimulating hormone (α-MSH) is a neuroendocrine-immune regulatory peptide with antimicrobial potential found in mammals as well as in organisms that lack adaptive immunity. Its precursor is expressed in phagocytes and epithelia, but posttranslational proteolytic processing is required to convert it to the active form. While in vitro antifungal activity against C. albicans was reported, including reduction of cell viability and germ tube formation, others observed only very mild effects on growth. Synthetic analogues have shown increased antifungal potency combined with an augmented half-life and only moderate hemolytic activity that would be necessary for realistic clinical use. The immunomodulatory effects of α-MSH include the regulation of nitric oxide production in macrophages and reduced chemotaxis in neutrophils. Its immunomodulatory and antimicrobial properties could be exploited for treatment of disorders in which inflammation and infection coexist.

Ib-AMPs are cysteine-rich AMPs, found in Impatiens balsamina seeds, comprising four closely related peptides (Ib-AMP1 to -4) derived from a single precursor protein. The structure, which is only 20 amino acids long, is characterized by intramolecular disulfide bridges important for retaining antifungal activity, as shown for Ib-AMP1 and -4 when tested against C. albicans and A. flavus. The mechanism of action is still unknown, but a distinct target in the plasma membrane was hypothesized.

Psoriasin is an AMP isolated from skin lesions of patients with psoriasis, with orthologues found in amphibians and cattle. In fact, it is the most prominent antibiotic peptide found on the skin of these individuals, who are rarely affected by bacterial and fungal infections. It is effective in vivo in a mouse lung model for A. fumigatus infection and in a guinea pig tinea pedis model for T. rubrum skin infection. Furthermore, in vitro experiments showed activity against other dermatophytes, such as T. mentagrophytes, M. canis, and Epidermophyton floccosum, which are currently difficult to treat. The target of this AMP is currently unknown, but its activity was inhibited by elevated zinc, suggesting that this compound interferes with zinc homeostasis and its sequestration could be a possible antimicrobial mechanism. Surprisingly, this AMP was not effective in killing C. albicans, although it was able to bind β-glucan and inhibit adhesion to surfaces.

VL-2397 (formerly ASP2397) is a cyclic hexapeptide isolated from Acremonium persicinum, which exhibited potent in vitro fungicidal activity against Aspergillus species (var. fumigatus, nidulans, flavus, and terreus), C. neoformans, C. glabrata, Candida kefyr, and Trichosporon asahii. Its mechanism of action is related to its structure, which resembles ferrichrome, an iron-chelating siderophore, and results in arrest of hyphal elongation. In a model of invasive pulmonary aspergillosis, immunocompromised mice treated with this compound survived longer and had lower lung fungal burdens than control animals. It was also efficacious against invasive candidiasis in neutropenic mice caused by drug-resistant C. glabrata. Moreover, a phase I study showed promising results regarding its safety and tolerability in healthy individuals.

VLL-28 is the first AMP isolated from the archaeal kingdom and is produced by proteolysis of a transcription factor of Sulfolobus islandicus. This cryptic peptide displays the same chemophysical and functional properties of typical AMPs, including broad-spectrum antibacterial and antifungal activities, particularly against C. albicans and C. parapsilosis via inhibition of growth and biofilm formation, including reduction of preformed biofilms. The antifungal mechanism is unknown, although the peptide seems to interact with the cell surface, either the wall and/or membrane, though in bacteria, it binds nucleic acids in the cytoplasm.

Scorpion venom is the source of a great number of peptides with antifungal activity, with similar characteristics, such as cationic character and structural flexibility. TistH is an alpha-helical peptide found in the venom of the scorpion Tityus stigmurus, part of the hypotensin family. It has moderate effects on C. albicans, C. tropicalis, T. rubrum, and A. flavus, with great strain-to-strain variability in susceptibility. It is characterized by the absence of cytotoxicity and in vivo inflammatory activity, but its mechanism is otherwise unknown. The maximum efficacy of this compound was obtained by incorporation within chitosan particles, providing improved antifungal effects (including on cell viability and biofilm formation), a prolonged released profile, and maintenance of biocompatibility. ToAP2 and NDBP5.7 are another two peptides produced by the scorpions Tityus obscurus and Opisthacanthus cayaporum, respectively, with remarkable antifungal activity on C. albicans. Some of the effects include membrane permeabilization with cell wall alteration, disruption of ultracellular structure, and inhibition of filamentation on early phase and mature biofilms. The therapeutic potential of the ToAP2 compound was supported by the protective activity in Galleria mellonella infection model and its synergism with AmB and fluconazole.

FUTURE PROSPECTS

The current antimycotic therapies are limited by the restricted choice of available compounds, and the increasing resistance of fungal pathogen further narrows the therapeutic options. The diversity of AMPs expands the development space for future antifungal therapeutics. Although escape strategies from the antifungal activity of the AMPs were described, including secretion of peptide effectors, AMP efflux pumps, and regulation of signaling pathways, they are, in fact, less prone to the development of resistance due to the rapid effect and the pharmacodynamic properties in comparison to conventional drugs.

However, the challenges to antimicrobial drug development are well known, as recently reviewed, and there are only a few examples of antifungal peptides being brought to clinical trials, including nikkomycin Z, aureobasidin A, and VL-2397. The biochemical and cell biological processes of the fungal pathogens are more closely related to those of the host compared to those of bacteria, representing one of the main scientific challenges of antifungal drug development but also presenting an opportunity that these complex molecules might be more specific and thus some may have low host toxicity. In addition to these scientific challenges, the design of clinical trials for antifungals poses several difficulties, including the costs related to the difficulty of finding eligible patients in a timely and unequivocal fashion.

As with small molecule antifungals, there is significant potential to use in silico peptide optimization to either design novel peptides de novo or improve naturally occurring ones. Further investigations on AMPs and their mechanisms of action are therefore required to elucidate novel antifungal strategies and pathogenicity mechanisms. The advancements in computational approaches, with predictions of drug target and resistance development, and the design of synthetic and semisynthetic peptides represent a valid and inexpensive strategy to reduce the costs related to antifungal compound discovery and design.

References 268

  1. 1.

    Vallabhaneni S, Mody RK, Walker T, Chiller T. 2016. The global burden of fungal diseases. Infect Dis Clin North Am 30:1–11. doi:.

    Not in our library10.1016/j.idc.2015.10.004

  2. 2.

    Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. 2019. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997-2016. Open Forum Infect Dis 6:S79–S94. doi:.

    Not in our library10.1093/ofid/ofy358

  3. 3.

    Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. 2018. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 360:739–742. doi:.

    Not in our library10.1126/science.aap7999

  4. 4.

    Lestrade PP, Bentvelsen RG, Schauwvlieghe AFAD, Schalekamp S, van der Velden WJFM, Kuiper EJ, van Paassen J, van der Hoven B, van der Lee HA, Melchers WJG, de Haan AF, van der Hoeven HL, Rijnders BJA, van der Beek MT, Verweij PE. 2019. Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study. Clin Infect Dis 68:1463–1471. doi:.

    Not in our library10.1093/cid/ciy859

  5. 5.

    Dubos RJ. 1939. Studies on a bactericidal agent extracted from a soil bacillus: I. Preparation of the agent. Its activity in vitro. J Exp Med 70:1–10. doi:.

    Not in our library10.1084/jem.70.1.1

  6. 6.

    Dubos RJ. 1939. Studies on a bactericidal agent extracted from a soil bacillus: II. Protective effect of the bactericidal agent against experimental Pneumococcus infections in mice. J Exp Med 70:11–18. doi:.

    Not in our library10.1084/jem.70.1.11

  7. 7.

    Landy M, Warren GH, RosenmanM SB, Colio LG. 1948. Bacillomycin: an antibiotic from Bacillus subtilis active against pathogenic fungi. Proc Soc Exp Biol Med 67:539–541. doi:.

    Not in our library10.3181/00379727-67-16367

  8. 8.

    Kang HK, Kim C, Seo CH, Park Y. 2017. The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J Microbiol 55:1–12. doi:.

    Not in our library10.1007/s12275-017-6452-1

  9. 9.
    Antifungal Peptides as Therapeutic Agents · 2020
    No notice
  10. 10.

    Delattin N, De Brucker K, De Cremer K, Pa Cammue B, Thevissen K. 2017. Antimicrobial peptides as a strategy to combat fungal biofilms. Curr Top Med Chem 17:604–612. doi:.

    Not in our library10.2174/1568026616666160713142228

  11. 11.

    Rios AC, Moutinho CG, Pinto FC, Del Fiol FS, Jozala A, Chaud MV, Vila MMDC, Teixeira JA, Balcão VM. 2016. Alternatives to overcoming bacterial resistances: state-of-the-art. Microbiol Res 191:51–80. doi:.

    Not in our library10.1016/j.micres.2016.04.008

  12. 12.

    Papagianni M. 2003. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv 21:465–499. doi:.

    Not in our library10.1016/s0734-9750(03)00077-6

  13. 13.

    Finking R, Marahiel MA. 2004. Biosynthesis of nonribosomal peptides. Annu Rev Microbiol 58:453–488. doi:.

    Not in our library10.1146/annurev.micro.58.030603.123615

  14. 14.

    Wang G. 2012. Post-translational modifications of natural antimicrobial peptides and strategies for peptide engineering. Curr Biotechnol 1:72–79. doi:.

    Not in our library10.2174/2211550111201010072

  15. 15.

    Pane K, Cafaro V, Avitabile A, Torres MDT, Vollaro A, De Gregorio E, Catania MR, Di Maro A, Bosso A, Gallo G, Zanfardino A, Varcamonti M, Pizzo E, Di Donato A, Lu TK, De La Fuente-Nunez C, Notomista E. 2018. Identification of novel cryptic multifunctional antimicrobial peptides from the human stomach enabled by a computational-experimental platform. ACS Synth Biol 7:2105–2115. doi:.

    Not in our library10.1021/acssynbio.8b00084

  16. 16.

    Jin Y, Hammer J, Pate M, Zhang Y, Zhu F, Zmuda E, Blazyk J. 2005. Antimicrobial activities and structures of two linear cationic peptide families with various amphipathic β-sheet and α-helical potentials. Antimicrob Agents Chemother 49:4957–4964. doi:.

    Not in our library10.1128/aac.49.12.4957-4964.2005

  17. 17.

    Cabiaux V, Agerberth B, Johansson J, Homblé F, Goormaghtigh E, Ruysschaert JM. 1994. Secondary structure and membrane interaction of PR‐39, a Pro+Arg‐rich antibacterial peptide. Eur J Biochem 224:1019–1027. doi:.

    Not in our library10.1111/j.1432-1033.1994.01019.x

  18. 18.

    Epand RM, Vogel HJ. 1999. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1462:11–28. doi:.

    Not in our library10.1016/s0005-2736(99)00198-4

  19. 19.

    Synge RL. 1945. The kinetics of low temperature acid hydrolysis of gramicidin and of some related dipeptides. Biochem J 39:351–355. doi:.

    Not in our library10.1042/bj0390351

  20. 20.

    Schibli DJ, Nguyen LT, Kernaghan SD, Rekdal Ø, Vogel HJ. 2006. Structure-function analysis of tritrpticin analogs: potential relationships between antimicrobial activities, model membrane interactions, and their micelle-bound NMR structures. Biophys J 91:4413–4426. doi:.

    Not in our library10.1529/biophysj.106.085837

  21. 21.

    Lundbaek JA, Collingwood SA, Ingólfsson HI, Kapoor R, Andersen OS. 2010. Lipid bilayer regulation of membrane protein function: gramicidin channels as molecular force probes. J R Soc Interface 7:373–395. doi:.

    Not in our library10.1098/rsif.2009.0443

  22. 22.

    Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3:238–250. doi:.

    Not in our library10.1038/nrmicro1098

  23. 23.
    Characterization of Antimicrobial Peptides toward the Development of Novel Antibiotics · 2013
    No notice
  24. 24.

    Mücke P-A, Maaß S, Kohler TP, Hammerschmidt S, Becher D. 2020. Proteomic adaptation of Streptococcus pneumoniae to the human antimicrobial peptide LL-37. Microorganisms 8:413. doi:.

    Not in our library10.3390/microorganisms8030413

  25. 25.

    Yin J, Meng Q, Cheng D, Fu J, Luo Q, Liu Y, Yu Z. 2020. Mechanisms of bactericidal action and resistance of polymyxins for Gram-positive bacteria. Appl Microbiol Biotechnol 104:3771–3780. doi:.

    Not in our library10.1007/s00253-020-10525-y

  26. 26.

    El Shazely B, Yu G, Johnston PR, Rolff J. 2020. Resistance evolution against antimicrobial peptides in Staphylococcus aureus alters pharmacodynamics beyond the MIC. Front Microbiol 11:103. doi:.

    Not in our library10.3389/fmicb.2020.00103

  27. 27.

    Drlica K, Zhao X. 2007. Mutant selection window hypothesis updated. Clin Infect Dis 44:681–688. doi:.

    Not in our library10.1086/511642

  28. 28.
    Combination Effects of Antimicrobial Peptides · 2016
    No notice
  29. 29.

    Fantner GE, Barbero RJ, Gray DS, Belcher AM. 2010. Kinetics of antimicrobial peptide activity measured on individual bacterial cells using high-speed atomic force microscopy. Nat Nanotechnol 5:280–285. doi:.

    Not in our library10.1038/nnano.2010.29

  30. 30.

    Yu G, Baeder DY, Regoes RR, Rolff J. 2018. Predicting drug resistance evolution: insights from antimicrobial peptides and antibiotics. Proc Biol Sci 285:20172687. doi:.

    Not in our library10.1098/rspb.2017.2687

  31. 31.

    De Lucca AJ, Walsh TJ. 1999. Antifungal peptides: novel therapeutic compounds against emerging pathogens. Antimicrob Agents Chemother 43:1–11. doi:.

    Not in our library10.1128/aac.43.1.1

  32. 32.

    Nguyen LT, Haney EF, Vogel HJ. 2011. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol 29:464–472. doi:.

    Not in our library10.1016/j.tibtech.2011.05.001

  33. 33.

    Rapaport D, Shai Y. 1991. Interaction of fluorescently labeled pardaxin and its analogues with lipid bilayers. J Biol Chem 266:23769–23775.

    Not in our library

  34. 34.

    Yamamoto T, Umegawa Y, Yamagami M, Suzuki T, Tsuchikawa H, Hanashima S, Matsumori N, Murata M. 2019. The perpendicular orientation of amphotericin B methyl ester in hydrated lipid bilayers supports the barrel-stave model. Biochemistry 58:2282–2291. doi:.

    Not in our library10.1021/acs.biochem.9b00180

  35. 35.

    Vanden Bossche H, Marichal P, Odds FC. 1994. Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2:393–400. doi:.

    Not in our library10.1016/0966-842x(94)90618-1

  36. 36.

    Anderson TM, Clay MC, Cioffi AG, Diaz KA, Hisao GS, Tuttle MD, Nieuwkoop AJ, Comellas G, Maryum N, Wang S, Uno BE, Wildeman EL, Gonen T, Rienstra CM, Burke MD. 2014. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol 10:400–406. doi:.

    Not in our library10.1038/nchembio.1496

  37. 37.

    Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, Burke MD. 2012. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U S A 109:2234–2239. doi:.

    Not in our library10.1073/pnas.1117280109

  38. 38.

    Mesa-Arango AC, Trevijano-Contador N, Román E, Sánchez-Fresneda R, Casas C, Herrero E, Argüelles JC, Pla J, Cuenca-Estrella M, Zaragoza O. 2014. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother 58:6627–6638. doi:.

    Not in our library10.1128/aac.03570-14

  39. 39.

    Pouny Y, Rapaport D, Shai Y, Mor A, Nicolas P. 1992. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogs with phospholipid membranes. Biochemistry 31:12416–12423. doi:.

    Not in our library10.1021/bi00164a017

  40. 40.

    Bechinger B. 1999. The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim Biophys Acta 1462:157–183. doi:.

    Not in our library10.1016/s0005-2736(99)00205-9

  41. 41.

    Mor A, Nicolas P. 1994. Isolation and structure of novel defensive peptides from frog skin. Eur J Biochem 219:145–154. doi:.

    Not in our library10.1111/j.1432-1033.1994.tb19924.x

  42. 42.

    Bergaoui I, Zairi A, Tangy F, Aouni M, Selmi B, Hani K. 2013. In vitro antiviral activity of dermaseptin S4 and derivatives from amphibian skin against herpes simplex virus type 2. J Med Virol 85:272–281. doi:.

    Not in our library10.1002/jmv.23450

  43. 43.

    Belmadani A, Semlali A, Rouabhia M. 2018. Dermaseptin-S1 decreases Candida albicans growth, biofilm formation and the expression of hyphal wall protein 1 and aspartic protease genes. J Appl Microbiol 125:72–83. doi:.

    Not in our library10.1111/jam.13745

  44. 44.

    Sorensen KN, Kim KH, Takemoto JY. 1996. In vitro antifungal and fungicidal activities and erythrocyte toxicities of cyclic lipodepsinonapeptides produced by Pseudomonas syringae pv. syringae? Antimicrob Agents Chemother 40:2710–2713. doi:.

    Not in our library10.1128/aac.40.12.2710

  45. 45.

    Hutchison ML, Tester MA, Gross DC. 1995. Role of biosurfactant and ion channel-forming activities of syringomycin in transmembrane ion flux: a model for the mechanism of action in the plant-pathogen interaction. Mol Plant Microbe Interact 8:610–620. doi:.

    Not in our library10.1094/mpmi-8-0610

  46. 46.

    DeLucca AJ, Bland JM, Jacks TJ, Grimm C, Cleveland TE, Walsh TJ. 1997. Fungicidal activity of cecropin A. Antimicrob Agents Chemother 41:481–483. doi:.

    Not in our library10.1128/aac.41.2.481

  47. 47.

    Yun JE, Lee DG. 2016. Cecropin A-induced apoptosis is regulated by ion balance and glutathione antioxidant system in Candida albicans. IUBMB Life 68:652–662. doi:.

    Not in our library10.1002/iub.1527

  48. 48.

    Hallock KJ, Lee DK, Ramamoorthy A. 2003. MSI-78, an analogue of the magainin antimicrobial peptides, disrupts lipid bilayer structure via positive curvature strain. Biophys J 84:3052–3060. doi:.

    Not in our library10.1016/s0006-3495(03)70031-9

  49. 49.

    Turner J, Cho Y, Dinh NN, Waring AJ, Lehrer RI. 1998. Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42:2206–2214. doi:.

    Not in our library10.1128/aac.42.9.2206

  50. 50.

    den Hertog AL, van Marle J, van Veen HA, Van't Hof W, Bolscher JGM, Veerman ECI, Nieuw Amerongen AV. 2005. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J 388:689–695. doi:.

    Not in our library10.1042/bj20042099

  51. 51.

    Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M, Merluzzi L, Gennaro R. 1997. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J Biol Chem 272:13088–13093. doi:.

    Not in our library10.1074/jbc.272.20.13088

  52. 52.
    Human Antimicrobial Peptide LL-37 Inhibits Adhesion of Candida albicans by Interacting with Yeast Cell-Wall Carbohydrates · 2011
    No notice
  53. 53.

    Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, Simms-Waldrip TR, Xie Y, Hooper LV, Koh AY. 2015. Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med 21:808–814. doi:.

    Not in our library10.1038/nm.3871

  54. 54.

    Lipkin R, Pino-Angeles A, Lazaridis T. 2017. Transmembrane pore structures of β-hairpin antimicrobial peptides by all-atom simulations. J Phys Chem B 121:9126–9140. doi:.

    Not in our library10.1021/acs.jpcb.7b06591

  55. 55.

    Hancock RE. 2001. Cationic peptides: effectors in innate immunity and novel antimicrobials. Lancet Infect Dis 1:156–164. doi:.

    Not in our library10.1016/s1473-3099(01)00092-5

  56. 56.

    Benincasa M, Scocchi M, Pacor S, Tossi A, Nobili D, Basaglia G, Busetti M, Gennaro R. 2006. Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts. J Antimicrob Chemother 58:950–959. doi:.

    Not in our library10.1093/jac/dkl382

  57. 57.

    Gauldie J, Hanson JM, Rumjanek FD, Shipolini RA, Vernon CA. 1976. The peptide components of bee venom. Eur J Biochem 61:369–376. doi:.

    Not in our library10.1111/j.1432-1033.1976.tb10030.x

  58. 58.

    Yang L, Harroun TA, Weiss TM, Ding L, Huang HW. 2001. Barrel-stave model or toroidal model? A case study on melittin pores. Biophys J 81:1475–1485. doi:.

    Not in our library10.1016/s0006-3495(01)75802-x

  59. 59.

    Lee J, Lee DG. 2014. Melittin triggers apoptosis in Candida albicans through the reactive oxygen species-mediated mitochondria/caspase-dependent pathway. FEMS Microbiol Lett 355:36–42. doi:.

    Not in our library10.1111/1574-6968.12450

  60. 60.

    Park C, Lee DG. 2010. Melittin induces apoptotic features in Candida albicans. Biochem Biophys Res Commun 394:170–172. doi:.

    Not in our library10.1016/j.bbrc.2010.02.138

  61. 61.

    Park J, Kwon O, An HJ, Park KK. 2018. Antifungal effects of bee venom components on trichophyton rubrum: a novel approach of bee venom study for possible emerging antifungal agent. Ann Dermatol 30:202–210. doi:.

    Not in our library10.5021/ad.2018.30.2.202

  62. 62.

    Szekeres A, Leitgeb B, Kredics L, Antal Z, Hatvani L, Manczinger L, Vágvölgyi C. 2005. Peptaibols and related peptaibiotics of Trichoderma: a review. Acta Microbiol Immunol Hung 52:137–168. doi:.

    Not in our library10.1556/amicr.52.2005.2.2

  63. 63.

    Zhao P, Xue Y, Li X, Li J, Zhao Z, Quan C, Gao W, Zu X, Bai X, Feng S. 2019. Fungi-derived lipopeptide antibiotics developed since 2000. Peptides 113:52–65. doi:.

    Not in our library10.1016/j.peptides.2019.02.002

  64. 64.

    Chugh JK, Wallace BA. 2001. Peptaibols: models for ion channels. Biochem Soc Trans 29:565–570. doi:.

    Not in our library10.1042/bst0290565

  65. 65.

    Ishiyama D, Satou T, Senda H, Fujimaki T, Honda R, Kanazawa S. 2000. Heptaibin, a novel antifungal peptaibol antibiotic from Emericellopsis sp. BAUA8289. J Antibiot (Tokyo) 53:728–732. doi:.

    Not in our library10.7164/antibiotics.53.728

  66. 66.

    Touati I, Ruiz N, Thomas O, Druzhinina IS, Atanasova L, Tabbene O, Elkahoui S, Benzekri R, Bouslama L, Pouchus YF, Limam F. 2018. Hyporientalin A, an anti-Candida peptaibol from a marine Trichoderma orientale. World J Microbiol Biotechnol 34:98. doi:.

    Not in our library10.1007/s11274-018-2482-z

  67. 67.

    Oh SU, Yun BS, Lee SJ, Kim JH, Yoo ID. 2002. Atroviridins A-C and neoatroviridins A-D, novel peptaibol antibiotics produced by Trichoderma atroviride F80317. I. Taxonomy, fermentation, isolation and biological activities. J Antibiot 55:557–564. doi:.

    Not in our library10.7164/antibiotics.55.557

  68. 68.

    Mohamed-Benkada M, François Pouchus Y, Vérité P, Pagniez F, Caroff N, Ruiz N. 2016. Identification and biological activities of long-chain peptaibols produced by a marine-derived strain of Trichoderma longibrachiatum. Chem Biodivers 13:521–530. doi:.

    Not in our library10.1002/cbdv.201500159

  69. 69.

    Summers MY, Kong F, Feng X, Siegel MM, Janso JE, Graziani EI, Carter GT. 2007. Septocylindrins A and B: peptaibols produced by the terrestrial fungus Septocylindrium sp. LL-Z1518. J Nat Prod 70:391–396. doi:.

    Not in our library10.1021/np060571q

  70. 70.

    Sher Khan R, Iqbal A, Malak R, Shehryar K, Attia S, Ahmed T, Ali Khan M, Arif M, Mii M. 2019. Plant defensins: types, mechanism of action and prospects of genetic engineering for enhanced disease resistance in plants. 3 Biotech 9:192. doi:.

    Not in our library10.1007/s13205-019-1725-5

  71. 71.

    Thevissen K, Warnecke DC, François IEJA, Leipelt M, Heinz E, Ott C, Zähringer U, Thomma BPHJ, Ferket KKA, Cammue BPA. 2004. Defensins from insects and plants interact with fungal glucosylceramides. J Biol Chem 279:3900–3905. doi:.

    Not in our library10.1074/jbc.m311165200

  72. 72.

    Hayes BME, Bleackley MR, Wiltshire JL, Anderson MA, Traven A, Van Der Weerden NL. 2013. Identification and mechanism of action of the plant defensin NaD1 as a new member of the antifungal drug arsenal against Candida albicans. Antimicrob Agents Chemother 57:3667–3675. doi:.

    Not in our library10.1128/aac.00365-13

  73. 73.

    Games PD, dos Santos IS, Mello ÉO, Diz MSS, Carvalho AO, de Souza-Filho GA, Da Cunha M, Vasconcelos IM, Ferreira B dos S, Gomes VM. 2008. Isolation, characterization and cloning of a cDNA encoding a new antifungal defensin from Phaseolus vulgaris L. seeds. Peptides 29:2090–2100. doi:.

    Not in our library10.1016/j.peptides.2008.08.008

  74. 74.

    Mello EO, Ribeiro SFF, Carvalho AO, Santos IS, Da Cunha M, Santa-Catarina C, Gomes VM. 2011. Antifungal activity of PvD1 defensin involves plasma membrane permeabilization, inhibition of medium acidification, and induction of ROS in fungi cells. Curr Microbiol 62:1209–1217. doi:.

    Not in our library10.1007/s00284-010-9847-3

  75. 75.

    Thevissen K, Terras FRG, Broekaert WF. 1999. Permeabilization of fungal membranes by plant defensins inhibits fungal growth. Appl Environ Microbiol 65:5451–5458. doi:.

    Not in our library10.1128/aem.65.12.5451-5458.1999

  76. 76.

    Koo JC, Lee SY, Chun HJ, Cheong YH, Choi JS, Kawabata SI, Miyagi M, Tsunasawa S, Ha KS, Bae DW, Han CD, Lee BL, Cho MJ. 1998. Two hevein homologs isolated from the seed of Pharbitis nil L. exhibit potent antifungal activity. Biochim Biophys Acta 1382:80–90. doi:.

    Not in our library10.1016/s0167-4838(97)00148-9

  77. 77.

    Park SC, Lee JR, Kim JY, Hwang I, Nah JW, Cheong H, Park Y, Hahm KS. 2010. Pr-1, a novel antifungal protein from pumpkin rinds. Biotechnol Lett 32:125–130. doi:.

    Not in our library10.1007/s10529-009-0126-y

  78. 78.

    Thevissen K, Ghazi A, De Samblanx GW, Brownlee C, Osborn RW, Broekaert WF. 1996. Fungal membrane responses induced by plant defensins and thionins. J Biol Chem 271:15018–15025. doi:.

    Not in our library10.1074/jbc.271.25.15018

  79. 79.

    Taveira GB, Carvalho AO, Rodrigues R, Trindade FG, Da Cunha M, Gomes VM. 2016. Thionin-like peptide from Capsicum annuum fruits: mechanism of action and synergism with fluconazole against Candida species. BMC Microbiol 16:12. doi:.

    Not in our library10.1186/s12866-016-0626-6

  80. 80.

    Taveira GB, Mello ÉO, Carvalho AO, Regente M, Pinedo M, de La Canal L, Rodrigues R, Gomes VM. 2017. Antimicrobial activity and mechanism of action of a thionin-like peptide from Capsicum annuum fruits and combinatorial treatment with fluconazole against Fusarium solani. Biopolymers 108:e23008. doi:.

    Not in our library10.1002/bip.23008

  81. 81.

    Mathews M, Jia HP, Guthmiller JM, Losh G, Graham S, Johnson GK, Tack BF, McCray PB. 1999. Production of β-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect Immun 67:2740–2745. doi:.

    Not in our library10.1128/iai.67.6.2740-2745.1999

  82. 82.

    Krishnakumari V, Rangaraj N, Nagaraj R. 2009. Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3. Antimicrob Agents Chemother 53:256–260. doi:.

    Not in our library10.1128/aac.00470-08

  83. 83.

    Edgerton M, Koshlukova SE, Araujo MWB, Patel RC, Dong J, Bruenn JA. 2000. Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways. Antimicrob Agents Chemother 44:3310–3316. doi:.

    Not in our library10.1128/aac.44.12.3310-3316.2000

  84. 84.

    Basso V, Garcia A, Tran DQ, Schaal JB, Tran P, Ngole D, Aqeel Y, Tongaonkar P, Ouellette AJ, Selsted ME. 2018. Fungicidal potency and mechanisms of -defensins against multidrug-resistant Candida species. Antimicrob Agents Chemother 62:e00111-18. doi:.

    Not in our library10.1128/aac.00111-18

  85. 85.

    Lei S, Zhao H, Pang B, Qu R, Lian Z, Jiang C, Shao D, Huang Q, Jin M, Shi J. 2019. Capability of iturin from Bacillus subtilis to inhibit Candida albicans in vitro and in vivo. Appl Microbiol Biotechnol 103:4377–4392. doi:.

    Not in our library10.1007/s00253-019-09805-z

  86. 86.

    Klich MA, Lax AR, Bland JM. 1991. Inhibition of some mycotoxigenic fungi by iturin A, a peptidolipid produced by Bacillus subtilis. Mycopathologia 116:77–80. doi:.

    Not in our library10.1007/bf00436368

  87. 87.

    Maget-Dana R, Peypoux F. 1994. Iturins, a special class of pore-forming lipopeptides: biological and physicochemical properties. Toxicology 87:151–174. doi:.

    Not in our library10.1016/0300-483x(94)90159-7

  88. 88.

    Han Q, Wu F, Wang X, Qi H, Shi L, Ren A, Liu Q, Zhao M, Tang C. 2015. The bacterial lipopeptide iturins induce Verticillium dahliae cell death by affecting fungal signalling pathways and mediate plant defence responses involved in pathogen-associated molecular pattern-triggered immunity. Environ Microbiol 17:1166–1188. doi:.

    Not in our library10.1111/1462-2920.12538

  89. 89.

    Aranda FJ, Teruel JA, Ortiz A. 2005. Further aspects on the hemolytic activity of the antibiotic lipopeptide iturin A. Biochim Biophys Acta 1713:51–56. doi:.

    Not in our library10.1016/j.bbamem.2005.05.003

  90. 90.

    Latoud C, Peypoux F, Michel G, Genet R, Morgat JL. 1986. Interactions of antibiotics of the iturin group with human erythrocytes. Biochim Biophys Acta 856:526–535. doi:.

    Not in our library10.1016/0005-2736(86)90144-6

  91. 91.

    Mor A, Chartrel N, Vaudry H, Nicolas P. 1994. Skin peptide tyrosine-tyrosine, a member of the pancreatic polypeptide family: isolation, structure, synthesis, and endocrine activity. Proc Natl Acad Sci U S A 91:10295–10299. doi:.

    Not in our library10.1073/pnas.91.22.10295

  92. 92.

    Vouldoukis I, Shai Y, Nicolas P, Mor A. 1996. Broad spectrum antibiotic activity of skin-PYY. FEBS Lett 380:237–240. doi:.

    Not in our library10.1016/0014-5793(96)00050-6

  93. 93.

    Takesako K, Kuroda H, Inoue T, Haruna F, Yoshikawa Y, Kato I, Uchida K, Hiratani T, Yamaguchi H. 1993. Biological properties of aureobasidin A, a cyclic depsipeptide antifungal antibiotic. J Antibiot (Tokyo) 46:1414–1420. doi:.

    Not in our library10.7164/antibiotics.46.1414

  94. 94.

    Zhong W, Jeffries MW, Georgopapadakou NH. 2000. Inhibition of inositol phosphorylceramide synthase by aureobasidin A in Candida and Aspergillus species. Antimicrob Agents Chemother 44:651–653. doi:.

    Not in our library10.1128/aac.44.3.651-653.2000

  95. 95.

    Tan HW, Tay ST. 2013. The inhibitory effects of aureobasidin A on Candida planktonic and biofilm cells. Mycoses 56:150–156. doi:.

    Not in our library10.1111/j.1439-0507.2012.02225.x

  96. 96.

    Aeed PA, Young CL, Nagiec MM, Elhammer ÅP. 2009. Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A. Antimicrob Agents Chemother 53:496–504. doi:.

    Not in our library10.1128/aac.00633-08

  97. 97.

    Heidler SA, Radding JA. 2000. Inositol phosphoryl transferases from human pathogenic fungi. Biochim Biophys Acta 1500:147–152. doi:.

    Not in our library10.1016/s0925-4439(99)00097-6

  98. 98.

    Katsuki Y, Yamaguchi Y, Tani M. 2018. Overexpression of PDR16 confers resistance to complex sphingolipid biosynthesis inhibitor aureobasidin A in yeast Saccharomyces cerevisiae. FEMS Microbiol Lett 365:fnx255. doi:.

    Not in our library10.1093/femsle/fnx255

  99. 99.

    Vigers AJ, Roberts WK, Selitrennikoff CP. 1991. A new family of plant antifungal proteins. Mol Plant Microbe Interact 4:315–323. doi:.

    Not in our library10.1094/mpmi-4-315

  100. 100.

    Stevens DA, Calderon L, Martinez M, Clemons KV, Wilson SJ, Selitrennikoff CP. 2002. Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model. J Antimicrob Chemother 50:361–364. doi:.

    Not in our library10.1093/jac/dkf136

  101. 101.

    Trudel J, Grenier J, Potvin C, Asselin A. 1998. Several thaumatin-like proteins bind to β-1,3-glucans. Plant Physiol 118:1431–1438. doi:.

    Not in our library10.1104/pp.118.4.1431

  102. 102.

    Lee DG, Park Y, Kim HN, Kim HK, Kim P, II, Choi BH, Hahm KS. 2002. Antifungal mechanism of an antimicrobial peptide, HP (2–20), derived from N-terminus of Helicobacter pylori ribosomal protein L1 against Candida albicans. Biochem Biophys Res Commun 291:1006–1013. doi:.

    Not in our library10.1006/bbrc.2002.6548

  103. 103.

    Park SC, Kim MH, Hossain MA, Shin SY, Kim Y, Stella L, Wade JD, Park Y, Hahm KS. 2008. Amphipathic α-helical peptide, HP (2-20), and its analogues derived from Helicobacter pylori: pore formation mechanism in various lipid compositions. Biochim Biophys Acta 1778:229–241. doi:.

    Not in our library10.1016/j.bbamem.2007.09.020

  104. 104.

    Park Y, Hahm KS. 2005. Effects of N- and C-terminal truncation of HP (2-20) from Helicobacter pylori ribosomal protein L1 (RPL1) on its anti-microbial activity. Biotechnol Lett 27:193–199. doi:.

    Not in our library10.1007/s10529-004-7875-4

  105. 105.

    Ribeiro PD, Medina-Acosta E. 2003. Prevention of lethal murine candidiasis using HP (2-20), an antimicrobial peptide derived from the N-terminus of Helicobacter pylori ribosomal protein L1. Peptides 24:1807–1814. doi:.

    Not in our library10.1016/j.peptides.2003.08.021

  106. 106.

    López-Abarrategui C, Alba A, Silva ON, Reyes-Acosta O, Vasconcelos IM, Oliveira JTA, Migliolo L, Costa MP, Costa CR, Silva MRR, Garay HE, Dias SC, Franco OL, Otero-González AJ. 2012. Functional characterization of a synthetic hydrophilic antifungal peptide derived from the marine snail Cenchritis muricatus. Biochimie 94:968–974. doi:.

    Not in our library10.1016/j.biochi.2011.12.016

  107. 107.

    Vicente FEM, González-Garcia M, Diaz Pico E, Moreno-Castillo E, Garay HE, Rosi PE, Jimenez AM, Campos-Delgado JA, Rivera DG, Chinea G, Pietro RCLR, Stenger S, Spellerberg B, Kubiczek D, Bodenberger N, Dietz S, Rosenau F, Paixão MW, Ständker L, Otero-González AJ. 2019. Design of a helical-stabilized, cyclic, and nontoxic analogue of the peptide Cm-p5 with improved antifungal activity. ACS Omega 4:19081–19095. doi:.

    Not in our library10.1021/acsomega.9b02201

  108. 108.

    López-Abarrategui C, McBeth C, Mandal SM, Sun ZJ, Heffron G, Alba-Menéndez A, Migliolo L, Reyes-Acosta O, García-Villarino M, Nolasco DO, Falcão R, Cherobim MD, Dias SC, Brandt W, Wessjohann L, Starnbach M, Franco OL, Otero-González AJ. 2015. Cm-p5: an antifungal hydrophilic peptide derived from the coastal mollusk Cenchritis muricatus (Gastropoda: Littorinidae). FASEB J 29:3315–3325. doi:.

    Not in our library10.1096/fj.14-269860

  109. 109.

    Gow NAR, Latge J-P, Munro CA. 2017. The fungal cell wall: structure, biosynthesis, and function, p 267–292. In Hetiman J, Howlett BJ, Crous PW, Stukenbrock EH, James TY, Gow NAR, The fungal kingdom. ASM Press, Washington, DC.

    Not in our library

  110. 110.

    Brown GD, Gordon S. 2001. Immune recognition: a new receptor for β-glucans. Nature 413:36–37. doi:.

    Not in our library10.1038/35092620

  111. 111.

    Gow NAR, Netea MG, Munro CA, Ferwerda G, Bates S, Mora-Montes HM, Walker L, Jansen T, Jacobs L, Tsoni V, Brown GD, Odds FC, Van der Meer JWM, Brown AJP, Kullberg BJ. 2007. Immune recognition of Candida albicans beta-glucan by dectin-1. J Infect Dis 196:1565–1571. doi:.

    Not in our library10.1086/523110

  112. 112.

    Bills G, Li Y, Chen L, Yue Q, Niu XM, An Z. 2014. New insights into the echinocandins and other fungal non-ribosomal peptides and peptaibiotics. Nat Prod Rep 31:1348–1375. doi:.

    Not in our library10.1039/c4np00046c

  113. 113.

    Douglas CM. 2001. Fungal beta(1,3)-d-glucan synthesis. Med Mycol 39 Suppl 1:55–66. doi:.

    Not in our library10.1080/mmy.39.1.55.66

  114. 114.

    Perlin DS. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10:121–130. doi:.

    Not in our library10.1016/j.drup.2007.04.002

  115. 115.

    Hensens OD, Liesch JM, Zink DL, Smith JL, Wichmann CF, Schwartz RE. 1992. Pneumocandins from Zalerion arboricola. III. Structure elucidation. J Antibiot (Tokyo) 45:1875–1885. doi:.

    Not in our library10.7164/antibiotics.45.1875

  116. 116.

    Debono M, Gordee RS. 1994. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 48:471–497. doi:.

    Not in our library10.1146/annurev.mi.48.100194.002351

  117. 117.

    Benz F, Knüsel F, Nüesch J, Treichler H, Voser W, Nyfeler R, Keller‐Schierlein W. 1974. Stoffwechselprodukte von Mikroorganismen 143. Mitteilung. Echinocandin B, ein neuartiges polypeptid‐antibioticum aus Aspergillus nidulans var. echinulatus: isolierung und bausteine. Helv Chim Acta 57:2459–2477. doi:.

    Not in our library10.1002/hlca.19740570818

  118. 118.

    Debono M, Abbott BJ, Turner JR, Howard LC, Gordee RS, Hunt AS, Barnhart M, Molloy RM, Willard KE, Fukuda D. 1988. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann N Y Acad Sci 544:152–167. doi:.

    Not in our library10.1111/j.1749-6632.1988.tb40398.x

  119. 119.

    Barrett D. 2002. From natural products to clinically useful antifungals. Biochim Biophys Acta 1587:224–233. doi:.

    Not in our library10.1016/s0925-4439(02)00085-6

  120. 120.

    Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18:19–37. doi:.

    Not in our library10.1111/1469-0691.12039

  121. 121.

    Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Herbrecht R, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Verweij PE, Viscoli C, Ullmann AJ. 2012. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. for integrated oncology. Clin Microbiol Infect 18:38–52. doi:.

    Not in our library10.1111/1469-0691.12040

  122. 122.

    Bartizal K, Abruzzo G, Trainor C, Krupa D, Nollstadt K, Schmatz D, Schwartz R, Hammond M, Balkovec J, Vanmiddlesworth F. 1992. In vitro antifungal activities and in vivo efficacies of 1,3-beta-d-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother 36:1648–1657. doi:.

    Not in our library10.1128/aac.36.8.1648

  123. 123.

    Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, Balkovec JM, Bouffard AF, Dropinski JF, Rosen H, Kropp H, Bartizal K. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 41:2333–2338. doi:.

    Not in our library10.1128/aac.41.11.2333

  124. 124.

    Espinel-Ingroff A. 2001. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39:954–958. doi:.

    Not in our library10.1128/jcm.39.3.954-958.2001

  125. 125.

    Hector RF, Bierer DE. 2011. New β-glucan inhibitors as antifungal drugs. Expert Opin Ther Pat 21:1597–1610. doi:.

    Not in our library10.1517/13543776.2011.603899

  126. 126.

    Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlin DS. 2014. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 58:1248–1251. doi:.

    Not in our library10.1128/aac.02145-13

  127. 127.

    Pfaller MA, Messer SA, Motyl MR, Jones RN, Castanheira M. 2013. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). J Antimicrob Chemother 68:858–863. doi:.

    Not in our library10.1093/jac/dks466

  128. 128.

    Traxler P, Gruner J, Auden JAL. 1977. Papulacandins, a new family of antibiotics with antifungal activity. I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D And E. J Antibiot (Tokyo) 30:289–296. doi:.

    Not in our library10.7164/antibiotics.30.289

  129. 129.

    Ohyama T, Iwadate-Kurihara Y, Hosoya T, Ishikawa T, Miyakoshi S, Hamano K, Inukai M. 2002. F-10748 A1, A2, B1, B2, C1, C2, D1, and D2, novel papulacandins. J Antibiot (Tokyo) 55:758–763. doi:.

    Not in our library10.7164/antibiotics.55.758

  130. 130.

    Bills GF, Yue Q, Chen L, Li Y, An Z, Frisvad JC. 2016. Aspergillus mulundensis sp. nov., a new species for the fungus producing the antifungal echinocandin lipopeptides, mulundocandins. J Antibiot (Tokyo) 69:141–148. doi:.

    Not in our library10.1038/ja.2015.105

  131. 131.

    Hochlowski JE, Whittern DN, Buko A, Alder L, McAlpine JB. 1995. Fusacandins A and B; novel antifungal antibiotics of the papulacandin class from Fusarium sambucinum: II. Isolation and structural elucidation. J Antibiot (Tokyo) 48:614–618. doi:.

    Not in our library10.7164/antibiotics.48.614

  132. 132.

    Gunawardana G, Rasmussen RR, Scherr M, Frost D, Brandt KD, Choi W, Jackson M, Karwowski JP, Sunga G, Malmberg LH, West P, Chen RH, Kadam S, Clement JJ, Mcalpine JB. 1997. Corynecandin: a novel antifungal glycolipid from Coryneum modonium. J Antibiot (Tokyo) 50:884–886. doi:.

    Not in our library10.7164/antibiotics.50.884

  133. 133.

    Sakai K, Suga T, Iwatsuki M, Chinen T, Nonaka K, Usui T, Asami Y, Ōmura S, Shiomi K. 2018. Pestiocandin, a new papulacandin class antibiotic isolated from Pestalotiopsis humus. J Antibiot (Tokyo) 71:1031–1035. doi:.

    Not in our library10.1038/s41429-018-0102-7

  134. 134.

    Iwamoto T, Fujie A, Nitta K, Hashimoto S, Okuhara M, Kohsaka M. 1994. WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties. J Antibiot (Tokyo) 47:1092–1097. doi:.

    Not in our library10.7164/antibiotics.47.1092

  135. 135.

    Martins IM, Cortés JCG, Muñoz J, Moreno MB, Ramos M, Clemente-Ramos JA, Durán A, Ribas JC. 2011. Differential activities of three families of specific β(1,3)glucan synthase inhibitors in wild-type and resistant strains of fission yeast. J Biol Chem 286:3484–3496. doi:.

    Not in our library10.1074/jbc.m110.174300

  136. 136.

    Iwata K, Yamamoto Y, Yamaguchi H, Hiratani T. 1982. In vitro studies of aculeacin A, a new antifungal antibiotic. J Antibiot (Tokyo) 35:203–209. doi:.

    Not in our library10.7164/antibiotics.35.203

  137. 137.

    Hawser S, Borgonovi M, Markus A, Isert D. 1999. Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro. J Antibiot (Tokyo) 52:305–310. doi:.

    Not in our library10.7164/antibiotics.52.305

  138. 138.

    Kyriakidis I, Tragiannidis A, Munchen S, Groll AH. 2017. Clinical hepatotoxicity associated with antifungal agents. Expert Opin Drug Saf 16:1449–165. doi:.

    Not in our library10.1080/14740338.2017.1270264

  139. 139.

    Mizuno K, Yagi A, Satoi S, Takada M, Hayashi M, Asano K, Matsuda T. 1977. Studies on aculeacin. I isolation and characterization of aculeacin A. J Antibiot (Tokyo) 30:297–302. doi:.

    Not in our library10.7164/antibiotics.30.297

  140. 140.
    Chitin synthesis and fungal pathogenesis · 2010
    No notice
  141. 141.

    Calderone RA, Braun PC. 1991. Adherence and receptor relationships of Candida albicans. Microbiol Rev 55:1–20. doi:.

    Not in our library10.1128/mmbr.55.1.1-20.1991

  142. 142.

    Chattaway FW, Holmes MR, Barlow AJ. 1968. Cell wall composition of the mycelial and blastospore forms of Candida albicans. J Gen Microbiol 51:367–376. doi:.

    Not in our library10.1099/00221287-51-3-367

  143. 143.

    Lee KK, MacCallum DM, Jacobsen MD, Walker LA, Odds FC, Gow NAR, Munro CA. 2012. Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo. Antimicrob Agents Chemother 56:208–217. doi:.

    Not in our library10.1128/aac.00683-11

  144. 144.

    Stenland CJ, Lis LG, Schendel FJ, Hahn NJ, Smart MA, Miller AL, Von Keitz MG, Gurvich VJ. 2013. A practical and scalable manufacturing process for an antifungal agent, nikkomycin Z. Org Process Res Dev 17:265–272. doi:.

    Not in our library10.1021/op3003294

  145. 145.

    Larson TM, Kendra DF, Busman M, Brown DW. 2011. Fusarium verticillioides chitin synthases CHS5 and CHS7 are required for normal growth and pathogenicity. Curr Genet 57:177–189. doi:.

    Not in our library10.1007/s00294-011-0334-6

  146. 146.

    Hector RF, Zimmer BL, Pappagianis D. 1990. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother 34:587–593. doi:.

    Not in our library10.1128/aac.34.4.587

  147. 147.

    Goldberg J, Connolly P, Schnizlein-Bick C, Durkin M, Kohler S, Smedema M, Brizendine E, Hector R, Wheat J. 2000. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. Antimicrob Agents Chemother 44:1624–1629. doi:.

    Not in our library10.1128/aac.44.6.1624-1629.2000

  148. 148.

    Clemons KV, Stevens DA. 1997. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother 41:2026–2028. doi:.

    Not in our library10.1128/aac.41.9.2026

  149. 149.

    Ganesan LT, Manavathu EK, Cutright JL, Alangaden GJ, Chandrasekar PH. 2004. In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus. Clin Microbiol Infect 10:961–966. doi:.

    Not in our library10.1111/j.1469-0691.2004.00996.x

  150. 150.

    Chiou CC, Mavrogiorgos N, Tillem E, Hector R, Walsh TJ. 2001. Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus. Antimicrob Agents Chemother 45:3310–3321. doi:.

    Not in our library10.1128/aac.45.12.3310-3321.2001

  151. 151.

    Fernandes C, Anjos J, Walker LA, Silva BMA, Cortes L, Mota M, Munro CA, Gow NAR, Gonçalves T. 2014. Modulation of alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors. Antimicrob Agents Chemother 58:2894–2904. doi:.

    Not in our library10.1128/aac.02647-13

  152. 152.

    Kovács R, Nagy F, Tóth Z, Bozó A, Balázs B, Majoros L. 2019. Synergistic effect of nikkomycin Z with caspofungin and micafungin against Candida albicans and Candida parapsilosis biofilms. Lett Appl Microbiol 69:271–278. doi:.

    Not in our library10.1111/lam.13204

  153. 153.

    Kim MK, Park HS, Kim CH, Park HM, Choi W. 2002. Inhibitory effect of nikkomycin Z on chitin synthases in Candida albicans. Yeast 19:341–349. doi:.

    Not in our library10.1002/yea.837

  154. 154.

    Segal E, Gottlieb S, Altboum Z, Gov Y, Berdicevsky I. 1997. Adhesion of Candida albicans to epithelial cells - effect of nikkomycin. Mycoses 40:33–39. doi:.

    Not in our library10.1111/j.1439-0507.1997.tb00168.x

  155. 155.

    Walker LA, Lee KK, Munro CA, Gow NAR. 2015. Caspofungin treatment of Aspergillus fumigatus results in ChsG-dependent upregulation of chitin synthesis and the formation of chitin-rich microcolonies. Antimicrob Agents Chemother 59:5932–5941. doi:.

    Not in our library10.1128/aac.00862-15

  156. 156.

    Walker LA, Gow NAR, Munro CA. 2013. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother 57:146–154. doi:.

    Not in our library10.1128/aac.01486-12

  157. 157.

    Pianalto KM, Billmyre BR, Telzrow CL, Alspaugh JA. 2019. Roles for stress response and cell wall biosynthesis pathways in caspofungin tolerance in Cryptococcus neoformans. Genetics 213:213–227. doi:.

    Not in our library10.1534/genetics.119.302290

  158. 158.

    Hector RF, Davidson AP, Johnson SM. 2005. Comparison of susceptibility of fungal isolates to lufenuron and nikkomycin Z alone or in combination with itraconazole. Am J Vet Res 66:1090–1093. doi:.

    Not in our library10.2460/ajvr.2005.66.1090

  159. 159.

    Nix DE, Swezey RR, Hector R, Galgiani JN. 2009. Pharmacokinetics of nikkomycin Z after single rising oral doses. Antimicrob Agents Chemother 53:2517–2521. doi:.

    Not in our library10.1128/aac.01609-08

  160. 160.

    Isono K, Asahi K, Suzuki S. 1969. Studies on polyoxins, antifungal antibiotics. XIII. The structure of polyoxins. J Am Chem Soc 91:7490–7505. doi:.

    Not in our library10.1021/ja01054a045

  161. 161.

    Kakiki K, Misato T, Hori M, Eguchi J. 1974. Studies on the mode of action of polyoxins. VI. Effect of polyoxin B on chitin synthesis in polyoxin-sensitive and resistant strains of Alternaria kikuchiana. J Antibiot (Tokyo) 27:260–266. doi:.

    Not in our library10.7164/antibiotics.27.260

  162. 162.

    Osada H. 2019. Discovery and applications of nucleoside antibiotics beyond polyoxin. J Antibiot (Tokyo) 72:855–864. doi:.

    Not in our library10.1038/s41429-019-0237-1

  163. 163.

    Becker JM, Covert NL, Shenbagamurthi P, Steinfeld AS, Naider F. 1983. Polyoxin D inhibits growth of zoopathogenic fungi. Antimicrob Agents Chemother 23:926–929. doi:.

    Not in our library10.1128/aac.23.6.926

  164. 164.

    Alcouloumre MS, Ghannoum MA, Ibrahim AS, Selsted ME, Edwards JE. 1993. Fungicidal properties of defensin NP-1 and activity against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 37:2628–2632. doi:.

    Not in our library10.1128/aac.37.12.2628

  165. 165.

    Levitz SM, Selsted ME, Ganz T, Lehrer RI, Diamond RD, Levitz SM, Selsted ME, Ganz T, Lehrer RI, Diamond RD. 1986. In vitro killing of spores and hyphae of Aspergillus fumigatus and Rhizopus oryzae by rabbit neutrophil cationic peptides and bronchoalveolar macrophages. J Infect Dis 154:483–489. doi:.

    Not in our library10.1093/infdis/154.3.483

  166. 166.

    Segal GP, Lehrer RI, Selsted ME. 1985. In vitro effect of phagocyte cationic peptides on Coccidioides immitis. J Infect Dis 151:890–894. doi:.

    Not in our library10.1093/infdis/151.5.890

  167. 167.

    Selsted ME, Szklarek D, Ganz T, Lehrer RI. 1985. Activity of rabbit leukocyte peptides against Candida albicans. Infect Immun 49:202–206. doi:.

    Not in our library10.1128/iai.49.1.202-206.1985

  168. 168.

    Vijayakumar EKS, Roy K, Chatterjee S, Deshmukh SK, Ganguli BN, Fehlhaber HW, Kogler H. 1996. Arthrichitin. A new cell wall active metabolite from Arthrinium phaeospermum. J Org Chem 61:6591–6593. doi:.

    Not in our library10.1021/jo960769n

  169. 169.

    Iwamoto T, Fujie A, Tsurumi Y, Nitta K, Hashimoto S, Okuhara M. 1990. FR900403, a new antifungal antibiotic produced by a Kernia sp. J Antibiot (Tokyo) 43:1183–1185. doi:.

    Not in our library10.7164/antibiotics.43.1183

  170. 170.
    Mannosylation in C andida albicans : role in cell wall function and immune recognition · 2013
    No notice
  171. 171.

    Munro CA, Bates S, Buurman ET, Hughes HB, Maccallum DM, Bertram G, Atrih A, Ferguson MAJ, Bain JM, Brand A, Hamilton S, Westwater C, Thomson LM, Brown AJP, Odds FC, Gow NAR. 2005. Mnt1p and Mnt2p of Candida albicans are partially redundant alpha-1,2-mannosyltransferases that participate in O-linked mannosylation and are required for adhesion and virulence. J Biol Chem 280:1051–1060. doi:.

    Not in our library10.1074/jbc.m411413200

  172. 172.

    Timpel C, Zink S, Strahl-Bolsinger S, Schröppel K, Ernst J. 2000. Morphogenesis, adhesive properties, and antifungal resistance depend on the Pmt6 protein mannosyltransferase in the fungal pathogen Candida albicans. J Bacteriol 182:3063–3071. doi:.

    Not in our library10.1128/jb.182.11.3063-3071.2000

  173. 173.

    Prill SKH, Klinkert B, Timpel C, Gale CA, Schröppel K, Ernst JF. 2005. PMT family of Candida albicans: five protein mannosyltransferase isoforms affect growth, morphogenesis and antifungal resistance. Mol Microbiol 55:546–560. doi:.

    Not in our library10.1111/j.1365-2958.2004.04401.x

  174. 174.

    Sawada Y, Nishio M, Yamamoto H, Hatori M, Miyaki T, Konishi M, Oki T. 1990. New antifungal antibiotics, pradimicins D and E glycine analogs of pradimicins A and C. J Antibiot (Tokyo) 43:771–777. doi:.

    Not in our library10.7164/antibiotics.43.771

  175. 175.

    Oki T, Konishi M, Tomatsu K, Tomita K, Saitoh KI, Tsunakawa M, Nishio M, Miyaki T, Kawaguchi H. 1988. Pradimicin, a novel class of potent antifungal antibiotics. J Antibiot (Tokyo) 41:1701–1704. doi:.

    Not in our library10.7164/antibiotics.41.1701

  176. 176.

    Takeuchi T, Hara T, Naganawa H, Okada M, Hamada M, Umezawa H, Gomi S, Sezaki M, Kondo S. 1988. New antifungal antibiotics, benanomicins A and B from an actinomycete. J Antibiot (Tokyo) 41:807–811. doi:.

    Not in our library10.7164/antibiotics.41.807

  177. 177.

    Oki T, Tenmyo O, Hirano M, Tomatsu K, Kamei H. 1990. Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities. J Antibiot (Tokyo) 43:763–770. doi:.

    Not in our library10.7164/antibiotics.43.763

  178. 178.

    Yasuoka A, Oka S, Komuro K, Shimizu H, Kitada K, Nakamura Y, Shibahara S, Takeuchi T, Kondo S, Shimada K, Kimura S. 1995. Successful treatment of Pneumocystis carinii pneumonia in mice with benanomicin a (ME1451). Antimicrob Agents Chemother 39:720–724. doi:.

    Not in our library10.1128/aac.39.3.720

  179. 179.

    Ueki T, Numata K, Sawada Y, Nakajima T, Fukagawa Y, Oki T. 1993. Studies on the mode of antifungal action of pradimicin antibiotics I. Lectin-mimic binding of BMY-28864 to yeast mannan in the presence of calcium. J Antibiot (Tokyo) 46:149–161. doi:.

    Not in our library10.7164/antibiotics.46.149

  180. 180.

    Nakagawa Y, Doi T, Takegoshi K, Sugahara T, Akase D, Aida M, Tsuzuki K, Watanabe Y, Tomura T, Ojika M, Igarashi Y, Hashizume D, Ito Y. 2019. Molecular basis of mannose recognition by pradimicins and their application to microbial cell surface imaging. Cell Chem Biol 26:950.e8–959.e8. doi:.

    Not in our library10.1016/j.chembiol.2019.03.013

  181. 181.

    Watanabe M, Tohyama H, Hiratani T, Watabe H, Inoue S, Kondo SI, Takeuchi T, Yamaguchi H. 1997. Mode of antifungal action of benanomicin A in Saccharomyces cerevisiae. J Antibiot (Tokyo) 50:1042–1051. doi:.

    Not in our library10.7164/antibiotics.50.1042

  182. 182.

    Hiramoto F, Nomura N, Furumai T, Oki T, Igarashi Y. 2003. Apoptosis-like cell death of Saccharomyces cerevisiae induced by a mannose-binding antifungal antibiotic, pradimicin. J Antibiot (Tokyo) 56:768–772. doi:.

    Not in our library10.7164/antibiotics.56.768

  183. 183.

    Uyterhoeven ET, Butler CH, Ko D, Elmore DE. 2008. Investigating the nucleic acid interactions and antimicrobial mechanism of buforin II. FEBS Lett 582:1715–1718. doi:.

    Not in our library10.1016/j.febslet.2008.04.036

  184. 184.

    Zhao P, Xue Y, Gao W, Li J, Zu X, Fu D, Feng S, Bai X, Zuo Y, Li P. 2018. Actinobacteria-derived peptide antibiotics since 2000. Peptides 103:48–59. doi:.

    Not in our library10.1016/j.peptides.2018.03.011

  185. 185.

    Rathod BB, Korasapati R, Sripadi P, Reddy Shetty P. 2018. Novel actinomycin group compound from newly isolated Streptomyces sp. RAB12: isolation, characterization, and evaluation of antimicrobial potential. Appl Microbiol Biotechnol 102:1241–1250. doi:.

    Not in our library10.1007/s00253-017-8696-4

  186. 186.

    Ortega E, Algarra I, Serrano MJ, Alvarez de Cienfuegos G, Gaforio JJ. 2001. The use of 7-amino-actinomycin D in the analysis of Candida albicans phagocytosis and opsonization. J Immunol Methods 253:189–193. doi:.

    Not in our library10.1016/s0022-1759(01)00358-1

  187. 187.

    Selsted ME, Novotny MJ, Morris WL, Tang YQ, Smith W, Cullor JS. 1992. Indolicidin, a novel bactericidal tridecapeptide amide from neutrophils. J Biol Chem 267:4292–4295.

    Not in our library

  188. 188.

    Giacometti A, Cirioni O, Barchiesi F, Caselli F, Scalise G. 1999. In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. J Antimicrob Chemother 44:403–406. doi:.

    Not in our library10.1093/jac/44.3.403

  189. 189.

    Lee DG, Kim HK, Kim SA, Park Y, Park SC, Jang SH, Hahm KS. 2003. Fungicidal effect of indolicidin and its interaction with phospholipid membranes. Biochem Biophys Res Commun 305:305–310. doi:.

    Not in our library10.1016/s0006-291x(03)00755-1

  190. 190.

    Marchand C, Krajewski K, Lee HF, Antony S, Johnson AA, Amin R, Roller P, Kvaratskhelia M, Pommier Y. 2006. Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Res 34:5157–5165. doi:.

    Not in our library10.1093/nar/gkl667

  191. 191.

    Subbalakshmi C, Sitaram N. 1998. Mechanism of antimicrobial action of indolicidin. FEMS Microbiol Lett 160:91–96. doi:.

    Not in our library10.1111/j.1574-6968.1998.tb12896.x

  192. 192.

    Ahmad I, Perkins WR, Lupan DM, Selsted ME, Janoff AS. 1995. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim Biophys Acta 1237:109–114. doi:.

    Not in our library10.1016/0005-2736(95)00087-j

  193. 193.

    Rahimi H, Roudbarmohammadi S, Hamid Delavari H, Roudbary M. 2019. Antifungal effects of indolicidin-conjugated gold nanoparticles against fluconazole-resistant strains of Candida albicans isolated from patients with burn infection. Int J Nanomedicine 14:5323–5338. doi:.

    Not in our library10.2147/ijn.s207527

  194. 194.

    Farzanegan A, Roudbary M, Falahati M, Khoobi M, Gholibegloo E, Farahyar S, Karimi P, Khanmohammadi M. 2018. Synthesis, characterization and antifungal activity of a novel formulated nanocomposite containing indolicidin and graphene oxide against disseminated candidiasis. J Mycol Med 28:628–636. doi:.

    Not in our library10.1016/j.mycmed.2018.07.009

  195. 195.

    Park CB, Kim HS, Kim SC. 1998. Mechanism of action of the antimicrobial peptide buforin II. Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun 244:253–257. doi:.

    Not in our library10.1006/bbrc.1998.8159

  196. 196.

    Cho JH, Sung BH, Kim SC. 2009. Buforins: histone H2A-derived antimicrobial peptides from toad stomach. Biochim Biophys Acta 1788:1564–1569. doi:.

    Not in our library10.1016/j.bbamem.2008.10.025

  197. 197.

    Park CB, Yi KS, Matsuzaki K, Kim MS, Kim SC. 2000. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci U S A 97:8245–8250. doi:.

    Not in our library10.1073/pnas.150518097

  198. 198.

    Puri S, Edgerton M. 2014. How does it kill?: understanding the candidacidal mechanism of salivary histatin 5. Eukaryot Cell 13:958–964. doi:.

    Not in our library10.1128/ec.00095-14

  199. 199.

    Nikawa H, Jin C, Fukushima H, Makihira S, Hamada T. 2001. Antifungal activity of histatin-5 against non-albicans Candida species. Oral Microbiol Immunol 16:250–252. doi:.

    Not in our library10.1034/j.1399-302x.2001.160409.x

  200. 200.

    Helmerhorst EJ, Troxler RF, Oppenheim FG. 2001. The human salivary peptide histatin 5 exerts its antifungal activity through the formation of reactive oxygen species. Proc Natl Acad Sci U S A 98:14637–14642. doi:.

    Not in our library10.1073/pnas.141366998

  201. 201.

    Jang WS, Bajwa JS, Sun JN, Edgerton M. 2010. Salivary histatin 5 internalization by translocation, but not endocytosis, is required for fungicidal activity in Candida albicans. Mol Microbiol 77:354–370. doi:.

    Not in our library10.1111/j.1365-2958.2010.07210.x

  202. 202.

    Li XS, Reddy MS, Baev D, Edgerton M. 2003. Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5. J Biol Chem 278:28553–28561. doi:.

    Not in our library10.1074/jbc.m300680200

  203. 203.

    Baev D, Rivetta A, Vylkova S, Sun JN, Zeng GF, Slayman CL, Edgerton M. 2004. The TRK1 potassium transporter is the critical effector for killing of Candida albicans by the cationic protein, histatin 5. J Biol Chem 279:55060–55072. doi:.

    Not in our library10.1074/jbc.m411031200

  204. 204.

    Vylkova S, Jang WS, Li W, Nayyar N, Edgerton M. 2007. Histatin 5 initiates osmotic stress response in Candida albicans via activation of the Hog1 mitogen-activated protein kinase pathway. Eukaryot Cell 6:1876–1888. doi:.

    Not in our library10.1128/ec.00039-07

  205. 205.

    Norris HL, Kumar R, Ong CY, Xu D, Edgerton M. 2020. Zinc binding by histatin 5 promotes fungicidal membrane disruption in C. albicans and C. glabrata. J Fungi (Basel) 6:124. doi:.

    Not in our library10.3390/jof6030124

  206. 206.

    Kolaczkowska A, Kolaczkowski M, Sokolowska A, Miecznikowska H, Kubiak A, Rolka K, Polanowski A. 2010. The antifungal properties of chicken egg cystatin against Candida yeast isolates showing different levels of azole resistance. Mycoses 53:314–320. doi:.

    Not in our library10.1111/j.1439-0507.2009.01722.x

  207. 207.

    Guzmán-de-Peña DL, Correa-González AM, Valdés-Santiago L, León-Ramírez CG, Valdés-Rodríguez S. 2015. In vitro effect of recombinant amaranth cystatin (AhCPI) on spore germination, mycelial growth, stress response and cellular integrity of Aspergillus niger and Aspergillus parasiticus. Mycology 6:168–175. doi:.

    Not in our library10.1080/21501203.2015.1112857

  208. 208.

    Henskens YMC, Veerman ECL, Nieuw Amerongen AV. 1996. Cystatins in health disease. Biol Chem Hoppe Seyler 377:71–86. doi:.

    Not in our library10.1515/bchm3.1996.377.2.71

  209. 209.

    Blankenvoorde MF, Henskens YM, van't Hof W, Veerman EC, Nieuw Amerongen AV. 1996. Inhibition of the growth and cysteine proteinase activity of Porphyromonas gingivalis by human salivary cystatin S and chicken cystatin. Biol Chem 377:847–850.

    Not in our library

  210. 210.
    Natural Products from Cyanobacteria: Focus on Beneficial Activities · 2019
    No notice
  211. 211.

    Vestola J, Shishido TK, Jokela J, Fewer DP, Aitio O, Permi P, Wahlsten M, Wang H, Rouhiainen L, Sivonen K. 2014. Hassallidins, antifungal glycolipopeptides, are widespread among cyanobacteria and are the end-product of a nonribosomal pathway. Proc Natl Acad Sci U S A 111:E1909–E1917. doi:.

    Not in our library10.1073/pnas.1320913111

  212. 212.

    Marquez BL, Watts KS, Yokochi A, Roberts MA, Verdier-Pinard P, Jimenez JI, Hamel E, Scheuer PJ, Gerwick WH. 2002. Structure and absolute stereochemistry of hectochlorin, a potent stimulator of actin assembly. J Nat Prod 65:866–871. doi:.

    Not in our library10.1021/np0106283

  213. 213.

    Humisto A, Jokela J, Teigen K, Wahlsten M, Permi P, Sivonen K, Herfindal L. 2019. Characterization of the interaction of the antifungal and cytotoxic cyclic glycolipopeptide hassallidin with sterol-containing lipid membranes. Biochim Biophys Acta Biomembr 1861:1510–1521. doi:.

    Not in our library10.1016/j.bbamem.2019.03.010

  214. 214.

    Hoon LC, Kim S, Hyun B, Suh J, Woo YC, Kim C, Lim Y, Kim C. 1994. Cepacidine A, a novel antifungal antibiotic produced by Pseudomonas cepacia. I. Taxonomy, production, isolation and biological activity. J Antibiot (Tokyo) 47:1402–1405. doi:.

    Not in our library10.7164/antibiotics.47.1402

  215. 215.

    Graham CE, Cruz MR, Garsin DA, Lorenz MC. 2017. Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and virulence of Candida albicans. Proc Natl Acad Sci U S A 114:4507–4512. doi:.

    Not in our library10.1073/pnas.1620432114

  216. 216.
    Antifungal Activity of the <named-content content-type="genus-species">Enterococcus faecalis</named-content> Peptide EntV Requires Protease Cleavage and Disulfide Bond Formation · 2019
    Not checked
  217. 217.

    Arai T, Mikami Y, Fukushima K, Utsumi T, Yazawa K. 1973. A new antibiotic, leucinostatin, derived from Penicillium lilacinum. J Antibiot (Tokyo) 26:157–161. doi:.

    Not in our library10.7164/antibiotics.26.157

  218. 218.

    Shima A, Fukushima K, Arai T, Terada H. 1990. Dual inhibitory effects of the peptide antibiotics leucinostatins on oxidative phosphorylation in mitochondria. Cell Struct Funct 15:53–58. doi:.

    Not in our library10.1247/csf.15.53

  219. 219.

    Ishiyama A, Otoguro K, Iwatsuki M, Iwatsuki M, Namatame M, Nishihara A, Nonaka K, Kinoshita Y, Takahashi Y, Masuma R, Shiomi K, Yamada H, Omura S. 2009. In vitro and in vivo antitrypanosomal activities of three peptide antibiotics: leucinostatin A and B, alamethicin I and tsushimycin. J Antibiot (Tokyo) 62:303–308. doi:.

    Not in our library10.1038/ja.2009.32

  220. 220.

    Kawada M, Inoue H, Ohba SI, Masuda T, Momose I, Ikeda D. 2010. Leucinostatin A inhibits prostate cancer growth through reduction of insulin-like growth factor-I expression in prostate stromal cells. Int J Cancer 126:810–818. doi:.

    Not in our library10.1002/ijc.24915

  221. 221.

    Gräfe U, Ihn W, Ritzau M, Schade W, Stengel C, Schlegel B, Fleck WF, Künkel W, Härtl A, Gutsche W. 1995. Helioferins; novel antifungal lipopeptides from Mycogone rosea: screening, isolation, structures and biological properties. J Antibiot (Tokyo) 48:126–133. doi:.

    Not in our library10.7164/antibiotics.48.126

  222. 222.

    Fuji K, Fujita E, Takaishi Y, Fujita T, Arita I, Komatsu M, Hiratsuka N. 1978. New antibiotics, trichopolyns A and B: isolation and biological activity. Experientia 34:237–239. doi:.

    Not in our library10.1007/bf01944702

  223. 223.

    Mori Y, Suzuki M, Fukushima K, Arai T. 1983. Structure of leucinostatin B, an uncoupler on mitochondria. J Antibiot (Tokyo) 36:1084–1086. doi:.

    Not in our library10.7164/antibiotics.36.1084

  224. 224.

    Song B, Rong YJ, Zhao MX, Chi ZM. 2013. Antifungal activity of the lipopeptides produced by Bacillus amyloliquefaciens anti-CA against Candida albicans isolated from clinic. Appl Microbiol Biotechnol 97:7141–7150. doi:.

    Not in our library10.1007/s00253-013-5000-0

  225. 225.

    Tao Y, Mei Bie X, Xia Lv F, Zhen Zhao H, Xin Lu Z. 2011. Antifungal activity and mechanism of fengycin in the presence and absence of commercial surfactin against Rhizopus stolonifer. J Microbiol 49:146–150. doi:.

    Not in our library10.1007/s12275-011-0171-9

  226. 226.

    Krishnan N, Velramar B, Velu RK. 2019. Investigation of antifungal activity of surfactin against mycotoxigenic phytopathogenic fungus Fusarium moniliforme and its impact in seed germination and mycotoxicosis. Pestic Biochem Physiol 155:101–107. doi:.

    Not in our library10.1016/j.pestbp.2019.01.010

  227. 227.
    Optimization for the production of surfactin with a new synergistic antifungal activity. · 2012
    Not checked
  228. 228.

    Rautela R, Singh AK, Shukla A, Cameotra SS. 2014. Lipopeptides from Bacillus strain AR2 inhibits biofilm formation by Candida albicans. Antonie Van Leeuwenhoek 105:809–821. doi:.

    Not in our library10.1007/s10482-014-0135-2

  229. 229.

    Liu Y, Lu J, Sun J, Zhu X, Zhou L, Lu Z, Lu Y. 2019. C16-fengycin A affect the growth of Candida albicans by destroying its cell wall and accumulating reactive oxygen species. Appl Microbiol Biotechnol 103:8963–8975. doi:.

    Not in our library10.1007/s00253-019-10117-5

  230. 230.

    Yuan L, Zhang S, Wang Y, Li Y, Wang X, Yang Q. 2018. Surfactin inhibits membrane fusion during invasion of epithelial cells by enveloped viruses. J Virol 92:e00809-18. doi:.

    Not in our library10.1128/jvi.00809-18

  231. 231.

    Cutuli M, Cristiani S, Lipton JM, Catania A. 2000. Antimicrobial effects of α-MSH peptides. J Leukoc Biol 67:233–239. doi:.

    Not in our library10.1002/jlb.67.2.233

  232. 232.

    Rajora N, Ceriani G, Catania A, Star RA, Murphy MT, Lipton JM. 1996. α-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line. J Leukoc Biol 59:248–253. doi:.

    Not in our library10.1002/jlb.59.2.248

  233. 233.

    Luger TA, Schauer E, F T, Krutmann J, Ansel J, Schwarz A, Schwarz T. 1993. Production of immunosuppressing melanotropins by human keratinocytes. Ann N Y Acad Sci 680:567–570. doi:.

    Not in our library10.1111/j.1749-6632.1993.tb19741.x

  234. 234.

    Rauch I, Holzmeister S, Kofler B. 2009. Anti-Candida activity of α-melanocyte-stimulating hormone (α-MSH) peptides. J Leukoc Biol 85:371–372. doi:.

    Not in our library10.1189/jlb.1008614

  235. 235.

    Grieco P, Carotenuto A, Auriemma L, Limatola A, Di Maro S, Merlino F, Mangoni ML, Luca V, Di Grazia A, Gatti S, Campiglia P, Gomez-Monterrey I, Novellino E, Catania A. 2013. Novel α-MSH peptide analogues with broad spectrum antimicrobial activity. PLoS One 8:e61614. doi:.

    Not in our library10.1371/journal.pone.0061614

  236. 236.

    Star RA, Rajora N, Huang J, Stock RC, Catania A, Lipton JM. 1995. Evidence of autocrine modulation of macrophage nitric oxide synthase by α-melanocyte-stimulating hormone. Proc Natl Acad Sci U S A 92:8016–8020. doi:.

    Not in our library10.1073/pnas.92.17.8016

  237. 237.

    Catania A, Rajora N, Capsoni F, Minonzio F, Star RA, Lipton JM. 1996. The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro. Peptides 17:675–679. doi:.

    Not in our library10.1016/0196-9781(96)00037-x

  238. 238.

    Clemons KV, Shankar J, Stevens DA. 2016. Mycologic endocrinology. Adv Exp Med Biol 874:337–363. doi:.

    Not in our library10.1007/978-3-319-20215-0_16

  239. 239.

    Tailor RH, Acland DP, Attenborough S, Cammue BPA, Evans IJ, Osborn RW, Ray JA, Rees SB, Broekaert WF. 1997. A novel family of small cysteine-rich antimicrobial peptides from seed of Impatiens balsamina is derived from a single precursor protein. J Biol Chem 272:24480–24487. doi:.

    Not in our library10.1074/jbc.272.39.24480

  240. 240.

    Gun Lee D, Yub Shin S, Kim D-H, Yeol Seo M, Hyun Kang J, Lee Y, Lyong Kim K, Hahm K-S. 1999. Antifungal mechanism of a cysteine-rich antimicrobial peptide, Ib-AMP1, from Impatiens balsamina against Candida albicans. Biotechnol Lett 21:1047–1050. doi:.

    Not in our library10.1023/a:1005636610512

  241. 241.

    Thevissen K, François IEJA, Sijtsma L, Van Amerongen A, Schaaper WMM, Meloen R, Posthuma-Trumpie T, Broekaert WF, Cammue BPA. 2005. Antifungal activity of synthetic peptides derived from Impatiens balsamina antimicrobial peptides Ib-AMP1 and Ib-AMP4. Peptides 26:1113–1119. doi:.

    Not in our library10.1016/j.peptides.2005.01.008

  242. 242.

    Hein KZ, Takahashi H, Tsumori T, Yasui Y, Nanjoh Y, Toga T, Wu Z, Grötzinger J, Jung S, Wehkamp J, Schroeder BO, Schroeder JM, Morita E. 2015. Disulphide-reduced psoriasin is a human apoptosis inducing broad-spectrum fungicide. Proc Natl Acad Sci U S A 112:13039–13044. doi:.

    Not in our library10.1073/pnas.1511197112

  243. 243.

    Matthijs S, Hernalsteens JP, Roelants K. 2017. An orthologue of the host-defense protein psoriasin (S100A7) is expressed in frog skin. Dev Comp Immunol 67:395–403. doi:.

    Not in our library10.1016/j.dci.2016.08.012

  244. 244.

    Regenhard P, Leippe M, Schubert S, Podschun R, Kalm E, Grötzinger J, Looft C. 2009. Antimicrobial activity of bovine psoriasin. Vet Microbiol 136:335–340. doi:.

    Not in our library10.1016/j.vetmic.2008.12.001

  245. 245.

    Harder J, Schröder J-M. 2005. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 77:476–486. doi:.

    Not in our library10.1189/jlb.0704409

  246. 246.

    Harder J, Bartels J, Christophers E, Schroder JM. 1997. A peptide antibiotic from human skin. Nature 387:861. doi:.

    Not in our library10.1038/43088

  247. 247.

    Fritz P, Beck-Jendroschek V, Brasch J. 2012. Inhibition of dermatophytes by the antimicrobial peptides human β-defensin-2, ribonuclease 7 and psoriasin. Med Mycol 50:579–584. doi:.

    Not in our library10.3109/13693786.2012.660203

  248. 248.

    Gläser R, Harder J, Lange H, Bartels J, Christophers E, Schröder JM. 2005. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 6:57–64. doi:.

    Not in our library10.1038/ni1142

  249. 249.

    Brauner A, Alvendal C, Chromek M, Stopsack KH, Ehrström S, Schröder JM, Bohm-Starke N. 2018. Psoriasin, a novel anti-Candida albicans adhesin. J Mol Med (Berl) 96:537–545. doi:.

    Not in our library10.1007/s00109-018-1637-6

  250. 250.

    Nakamura I, Yoshimura S, Masaki T, Takase S, Ohsumi K, Hashimoto M, Furukawa S, Fujie A. 2017. ASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833. J Antibiot (Tokyo) 70:45–51. doi:.

    Not in our library10.1038/ja.2016.107

  251. 251.

    Dietl AM, Misslinger M, Aguiar MM, Ivashov V, Teis D, Pfister J, Decristoforo C, Hermann M, Sullivan SM, Smith LR, Haas H. 2019. The siderophore transporter Sit1 determines susceptibility to the antifungal VL-2397. Antimicrob Agents Chemother 63:e00807-19. doi:.

    Not in our library10.1128/aac.00807-19

  252. 252.

    Nakamura I, Ohsumi K, Takeda S, Katsumata K, Matsumoto S, Akamatsu S, Mitori H, Nakai T. 2019. ASP2397 is a novel natural compound that exhibits rapid and potent fungicidal activity against Aspergillus species through a specific transporter. Antimicrob Agents Chemother 63:e02689-18. doi:.

    Not in our library10.1128/aac.02689-18

  253. 253.

    Wiederhold NP, Najvar LK, Jaramillo R, Olivo M, Catano G, Sullivan SM. 2017. The novel antifungal VL-2397 demonstrates efficacy in an in vivo model of invasive candidiasis caused by wild-type and multi-drug resistant Candida glabrata. ASM Microbe, New Orleans, LA.

    Not in our library

  254. 254.

    Mammen MP, Armas D, Hughes FH, Hopkins AM, Fisher CL, Resch PA, Rusalov D, Sullivan SM, Smith LR. 2019. First-in-human phase 1 study to assess safety, tolerability, and pharmacokinetics of a novel antifungal drug, VL-2397, in healthy adults. Antimicrob Agents Chemother 63:e00969-19. doi:.

    Not in our library10.1128/aac.00969-19

  255. 255.

    Notomista E, Falanga A, Fusco S, Pirone L, Zanfardino A, Galdiero S, Varcamonti M, Pedone E, Contursi P. 2015. The identification of a novel Sulfolobus islandicus CAMP-like peptide points to archaeal microorganisms as cell factories for the production of antimicrobial molecules. Microb Cell Fact 14:126. doi:.

    Not in our library10.1186/s12934-015-0302-9

  256. 256.

    Roscetto E, Contursi P, Vollaro A, Fusco S, Notomista E, Catania MR. 2018. Antifungal and anti-biofilm activity of the first cryptic antimicrobial peptide from an archaeal protein against Candida spp. clinical isolates. Sci Rep 8:17570. doi:.

    Not in our library10.1038/s41598-018-35530-0

  257. 257.

    Guilhelmelli F, Vilela N, Smidt KS, de Oliveira MA, da Cunha Morales Álvares A, Rigonatto MCL, da Silva Costa PH, Tavares AH, de Freitas SM, Nicola AM, Franco OL, da Derengowski LS, Schwartz EF, Mortari MR, Bocca AL, Albuquerque P, Silva-Pereira I. 2016. Activity of scorpion venom-derived antifungal peptides against planktonic cells of Candida spp. and Cryptococcus neoformans and Candida albicans. Front Microbiol 7:1844. doi:.

    Not in our library10.3389/fmicb.2016.01844

  258. 258.

    Machado RJA, Estrela AB, Nascimento AKL, Melo MMA, Torres-Rêgo M, Lima EO, Rocha HAO, Carvalho E, Silva-Junior AA, Fernandes-Pedrosa MF. 2016. Characterization of TistH, a multifunctional peptide from the scorpion Tityus stigmurus: structure, cytotoxicity and antimicrobial activity. Toxicon 119:362–370. doi:.

    Not in our library10.1016/j.toxicon.2016.06.002

  259. 259.

    Torres-Rêgo M, Gláucia-Silva F, Rocha Soares KS, de Souza LBFC, Damasceno IZ, dos Santos-Silva E, Lacerda AF, Chaves GM, da Silva-Júnior AA, de Fernandes-Pedrosa MF. 2019. Biodegradable cross-linked chitosan nanoparticles improve anti-Candida and anti-biofilm activity of TistH, a peptide identified in the venom gland of the Tityus stigmurus scorpion. Mater Sci Eng C Mater Biol Appl 103:109830. doi:.

    Not in our library10.1016/j.msec.2019.109830

  260. 260.

    do Nascimento Dias J, de Souza Silva C, de Araújo AR, Souza JMT, de Holanda Veloso Júnior PH, Cabral WF, da Glória da Silva M, Eaton P, de Souza de Almeida Leite JR, Nicola AM, Albuquerque P, Silva-Pereira I. 2020. Mechanisms of action of antimicrobial peptides ToAP2 and NDBP-5.7 against Candida albicans planktonic and biofilm cells. Sci Rep 10:1–14. doi:.

    Not in our library10.1038/s41598-020-67041-2

  261. 261.

    Swidergall M, Ernst JF. 2014. Interplay between Candida albicans and the antimicrobial peptide armory. Eukaryot Cell 13:950–957. doi:.

    Not in our library10.1128/ec.00093-14

  262. 262.

    Yeung ATY, Gellatly SL, Hancock REW. 2011. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 68:2161–2176. doi:.

    Not in our library10.1007/s00018-011-0710-x

  263. 263.

    Rauseo AM, Coler-Reilly A, Larson L, Spec A. 2020. Hope on the horizon: novel fungal treatments in development. Open Forum Infect Dis 7:ofaa016. doi:.

    Not in our library10.1093/ofid/ofaa016

  264. 264.

    Rex JH, Walsh TJ, Nettleman M, Anaissie EJ, Bennett JE, Bow EJ, Carillo-Munoz AJ, Chavanet P, Cloud GA, Denning DW, de Pauw BE, Edwards JE, Jr, Hiemenz JW, Kauffman CA, Lopez-Berestein G, Martino P, Sobel JD, Stevens DA, Sylvester R, Tollemar J, Viscoli C, Viviani MA, Wu T. 2001. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis 33:95–106. doi:.

    Not in our library10.1086/320876

  265. 265.
    In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design · 2018
    No notice
  266. 266.

    Burkard TR, Rix U, Breitwieser FP, Superti-Furga G, Colinge J. 2010. A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib. PLoS Comput Biol 6:e1001001. doi:.

    Not in our library10.1371/journal.pcbi.1001001

  267. 267.

    Jena L, Waghmare P, Kashikar S, Kumar S, Harinath BC. 2014. Computational approach in understanding mechanism of action of isoniazid and drug resistance. Int J Mycobacteriol 3:276–282. doi:.

    Not in our library10.1016/j.ijmyco.2014.08.003

  268. 268.

    Blondelle SE, Lohner K. 2000. Combinatorial libraries: a tool to design antimicrobial and antifungal peptide analogues having lytic specificities for structure - activity relationship studies. Biopolymers 55:74–87. doi:.

    Not in our library10.1002/1097-0282(2000)55:1<74::aid-bip70>3.0.co;2-s

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.